0000855683 2026-01-01 2026-06-30 0000855683 2026-08-11 0000855683 2026-06-30 0000855683 2025-12-31 0000855683 us-gaap:NonrelatedPartyMember 2026-06-30 0000855683 us-gaap:NonrelatedPartyMember 2025-12-31 0000855683 us-gaap:RelatedPartyMember 2026-06-30 0000855683 us-gaap:RelatedPartyMember 2025-12-31 0000855683 2026-04-01 2026-06-30 0000855683 2025-04-01 2025-06-30 0000855683 2025-01-01 2025-06-30 0000855683 us-gaap:CommonStockMember 2025-12-31 0000855683 us-gaap:AdditionalPaidInCapitalMember 2025-12-31 0000855683 us-gaap:RetainedEarningsMember 2025-12-31 0000855683 us-gaap:TreasuryStockCommonMember 2025-12-31 0000855683 us-gaap:CommonStockMember 2026-03-31 0000855683 us-gaap:AdditionalPaidInCapitalMember 2026-03-31 0000855683 us-gaap:RetainedEarningsMember 2026-03-31 0000855683 us-gaap:TreasuryStockCommonMember 2026-03-31 0000855683 2026-03-31 0000855683 us-gaap:CommonStockMember 2024-12-31 0000855683 us-gaap:AdditionalPaidInCapitalMember 2024-12-31 0000855683 us-gaap:RetainedEarningsMember 2024-12-31 0000855683 us-gaap:TreasuryStockCommonMember 2024-12-31 0000855683 2024-12-31 0000855683 us-gaap:CommonStockMember 2025-03-31 0000855683 us-gaap:AdditionalPaidInCapitalMember 2025-03-31 0000855683 us-gaap:RetainedEarningsMember 2025-03-31 0000855683 us-gaap:TreasuryStockCommonMember 2025-03-31 0000855683 2025-03-31 0000855683 us-gaap:CommonStockMember 2026-01-01 2026-03-31 0000855683 us-gaap:AdditionalPaidInCapitalMember 2026-01-01 2026-03-31 0000855683 us-gaap:RetainedEarningsMember 2026-01-01 2026-03-31 0000855683 us-gaap:TreasuryStockCommonMember 2026-01-01 2026-03-31 0000855683 2026-01-01 2026-03-31 0000855683 us-gaap:CommonStockMember 2026-04-01 2026-06-30 0000855683 us-gaap:AdditionalPaidInCapitalMember 2026-04-01 2026-06-30 0000855683 us-gaap:RetainedEarningsMember 2026-04-01 2026-06-30 0000855683 us-gaap:TreasuryStockCommonMember 2026-04-01 2026-06-30 0000855683 us-gaap:CommonStockMember 2025-01-01 2025-03-31 0000855683 us-gaap:AdditionalPaidInCapitalMember 2025-01-01 2025-03-31 0000855683 us-gaap:RetainedEarningsMember 2025-01-01 2025-03-31 0000855683 us-gaap:TreasuryStockCommonMember 2025-01-01 2025-03-31 0000855683 2025-01-01 2025-03-31 0000855683 us-gaap:CommonStockMember 2025-04-01 2025-06-30 0000855683 us-gaap:AdditionalPaidInCapitalMember 2025-04-01 2025-06-30 0000855683 us-gaap:RetainedEarningsMember 2025-04-01 2025-06-30 0000855683 us-gaap:TreasuryStockCommonMember 2025-04-01 2025-06-30 0000855683 us-gaap:CommonStockMember 2026-06-30 0000855683 us-gaap:AdditionalPaidInCapitalMember 2026-06-30 0000855683 us-gaap:RetainedEarningsMember 2026-06-30 0000855683 us-gaap:TreasuryStockCommonMember 2026-06-30 0000855683 us-gaap:CommonStockMember 2025-06-30 0000855683 us-gaap:AdditionalPaidInCapitalMember 2025-06-30 0000855683 us-gaap:RetainedEarningsMember 2025-06-30 0000855683 us-gaap:TreasuryStockCommonMember 2025-06-30 0000855683 2025-06-30 0000855683 us-gaap:PrivatePlacementMember 2026-04-20 2026-04-20 0000855683 us-gaap:PrivatePlacementMember 2026-04-20 0000855683 MLSS:DentalFinishedGoodsMember 2026-06-30 0000855683 MLSS:DentalFinishedGoodsMember 2025-12-31 0000855683 MLSS:MedicalFinishedGoodsMember 2026-06-30 0000855683 MLSS:MedicalFinishedGoodsMember 2025-12-31 0000855683 MLSS:OfficersDirectorsAndOtherEmployeesMember 2026-06-30 0000855683 MLSS:OfficersDirectorsAndOtherEmployeesMember 2025-06-30 0000855683 MLSS:NonemployeesMember 2026-06-30 0000855683 MLSS:NonemployeesMember 2025-06-30 0000855683 srt:MaximumMember MLSS:TwentyTwentyEquityIncentivePlanMember us-gaap:CommonStockMember 2026-06-30 2026-06-30 0000855683 srt:MaximumMember MLSS:TwentyTwentyEquityIncentivePlanMember us-gaap:CommonStockMember us-gaap:SubsequentEventMember 2026-07-27 2026-07-27 0000855683 us-gaap:EmployeeStockOptionMember 2023-06-28 2023-06-28 0000855683 MLSS:TwoThousandTwentyPlanMember 2026-04-30 2026-04-30 0000855683 2026-04-30 0000855683 srt:MinimumMember 2026-04-30 2026-04-30 0000855683 srt:MaximumMember 2026-04-30 2026-04-30 0000855683 2026-04-30 2026-04-30 0000855683 us-gaap:CommonStockMember 2026-04-30 2026-04-30 0000855683 us-gaap:StockOptionMember 2026-01-01 2026-06-30 0000855683 srt:MinimumMember us-gaap:StockOptionMember 2026-06-30 0000855683 srt:MaximumMember us-gaap:StockOptionMember 2026-06-30 0000855683 MLSS:StockOptionOneMember 2026-01-01 2026-06-30 0000855683 MLSS:StockOptionOneMember 2026-06-30 0000855683 us-gaap:EmployeeStockOptionMember 2026-04-01 2026-06-30 0000855683 us-gaap:EmployeeStockOptionMember 2026-01-01 2026-06-30 0000855683 us-gaap:EmployeeStockOptionMember 2025-04-01 2025-06-30 0000855683 us-gaap:EmployeeStockOptionMember 2025-01-01 2025-06-30 0000855683 us-gaap:EmployeeStockOptionMember 2026-06-30 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2026-04-01 2026-06-30 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2026-01-01 2026-06-30 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2025-04-01 2025-06-30 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2025-01-01 2025-06-30 0000855683 us-gaap:RestrictedStockMember 2026-01-01 2026-01-01 0000855683 us-gaap:RestrictedStockMember 2026-01-01 2026-03-31 0000855683 us-gaap:RestrictedStockMember 2025-01-01 2025-03-31 0000855683 us-gaap:RestrictedStockMember 2026-01-01 2026-06-30 0000855683 us-gaap:RestrictedStockMember 2025-01-01 2025-06-30 0000855683 us-gaap:RestrictedStockMember 2026-03-31 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2026-01-01 2026-06-30 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2025-12-31 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2025-01-01 2025-12-31 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementEmployeeMember 2026-06-30 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2025-12-31 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2025-01-01 2025-12-31 0000855683 us-gaap:EmployeeStockOptionMember us-gaap:ShareBasedPaymentArrangementNonemployeeMember 2026-06-30 0000855683 us-gaap:RestrictedStockMember 2025-12-31 0000855683 us-gaap:RestrictedStockMember 2026-06-30 0000855683 us-gaap:CorporateNonSegmentMember 2026-04-01 2026-06-30 0000855683 us-gaap:OperatingSegmentsMember MLSS:DentalMember 2026-04-01 2026-06-30 0000855683 us-gaap:OperatingSegmentsMember MLSS:MedicalMember 2026-04-01 2026-06-30 0000855683 MLSS:GrandTotalMember 2026-04-01 2026-06-30 0000855683 us-gaap:CorporateNonSegmentMember 2025-04-01 2025-06-30 0000855683 us-gaap:OperatingSegmentsMember MLSS:DentalMember 2025-04-01 2025-06-30 0000855683 us-gaap:OperatingSegmentsMember MLSS:MedicalMember 2025-04-01 2025-06-30 0000855683 MLSS:GrandTotalMember 2025-04-01 2025-06-30 0000855683 us-gaap:CorporateNonSegmentMember 2026-01-01 2026-06-30 0000855683 us-gaap:OperatingSegmentsMember MLSS:DentalMember 2026-01-01 2026-06-30 0000855683 us-gaap:OperatingSegmentsMember MLSS:MedicalMember 2026-01-01 2026-06-30 0000855683 MLSS:GrandTotalMember 2026-01-01 2026-06-30 0000855683 us-gaap:CorporateNonSegmentMember 2025-01-01 2025-06-30 0000855683 us-gaap:OperatingSegmentsMember MLSS:DentalMember 2025-01-01 2025-06-30 0000855683 us-gaap:OperatingSegmentsMember MLSS:MedicalMember 2025-01-01 2025-06-30 0000855683 MLSS:GrandTotalMember 2025-01-01 2025-06-30 0000855683 us-gaap:OperatingSegmentsMember MLSS:DentalSegmentMember 2026-06-30 0000855683 us-gaap:OperatingSegmentsMember MLSS:MedicalSegmentMember 2026-06-30 0000855683 us-gaap:CorporateNonSegmentMember 2026-06-30 0000855683 us-gaap:OperatingSegmentsMember MLSS:DentalSegmentMember 2025-12-31 0000855683 us-gaap:OperatingSegmentsMember MLSS:MedicalSegmentMember 2025-12-31 0000855683 us-gaap:CorporateNonSegmentMember 2025-12-31 0000855683 MLSS:ECommerceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2026-04-01 2026-06-30 0000855683 MLSS:DistributorOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2026-04-01 2026-06-30 0000855683 MLSS:ECommerceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-04-01 2025-06-30 0000855683 MLSS:DistributorOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-04-01 2025-06-30 0000855683 MLSS:ECommerceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2026-01-01 2026-06-30 0000855683 MLSS:DistributorOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2026-01-01 2026-06-30 0000855683 MLSS:ECommerceMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-06-30 0000855683 MLSS:DistributorOneMember us-gaap:SalesRevenueNetMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-06-30 0000855683 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2026-01-01 2026-06-30 0000855683 MLSS:DistributorOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2026-01-01 2026-06-30 0000855683 MLSS:DistributorTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2026-01-01 2026-06-30 0000855683 MLSS:DistributorThreeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2026-01-01 2026-06-30 0000855683 us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-12-31 0000855683 MLSS:DistributorOneMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-12-31 0000855683 MLSS:DistributorTwoMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-12-31 0000855683 MLSS:DistributorThreeMember us-gaap:AccountsReceivableMember us-gaap:CustomerConcentrationRiskMember 2025-01-01 2025-12-31 0000855683 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2026-01-01 2026-06-30 0000855683 MLSS:SupplierOneMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember us-gaap:RelatedPartyMember 2026-01-01 2026-06-30 0000855683 MLSS:SupplierTwoMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember us-gaap:RelatedPartyMember 2026-01-01 2026-06-30 0000855683 MLSS:SupplierThreeMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember us-gaap:RelatedPartyMember 2026-01-01 2026-06-30 0000855683 us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember 2025-01-01 2025-12-31 0000855683 MLSS:SupplierOneMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember us-gaap:RelatedPartyMember 2025-01-01 2025-12-31 0000855683 MLSS:SupplierTwoMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember us-gaap:RelatedPartyMember 2025-01-01 2025-12-31 0000855683 MLSS:SupplierThreeMember us-gaap:AccountsPayableMember us-gaap:SupplierConcentrationRiskMember us-gaap:RelatedPartyMember 2025-01-01 2025-12-31 0000855683 MLSS:UnitedSystemsMember 2026-04-01 2026-06-30 0000855683 MLSS:UnitedSystemsMember 2026-01-01 2026-06-30 0000855683 MLSS:UnitedSystemsMember 2025-04-01 2025-06-30 0000855683 MLSS:UnitedSystemsMember 2025-01-01 2025-06-30 0000855683 MLSS:UnitedSystemsMember 2026-06-30 0000855683 MLSS:UnitedSystemsMember 2025-12-31 0000855683 MLSS:DirectorClinicalAffairMember 2026-04-01 2026-06-30 0000855683 MLSS:DirectorClinicalAffairMember 2026-01-01 2026-06-30 0000855683 MLSS:DirectorClinicalAffairMember 2025-04-01 2025-06-30 0000855683 MLSS:DirectorClinicalAffairMember 2025-01-01 2025-06-30 0000855683 MLSS:DirectorClinicalAffairMember 2026-06-30 0000855683 MLSS:DirectorClinicalAffairMember 2025-12-31 0000855683 MLSS:MrOsserViceChairmanOfBoardMember MLSS:EmploymentAgreementMember 2017-07-31 2017-07-31 0000855683 MLSS:MrOsserViceChairmanOfBoardMember MLSS:ConsultingAgreementMember 2017-07-31 2017-07-31 0000855683 us-gaap:EmployeeStockOptionMember MLSS:MrOsserViceChairmanOfBoardMember 2021-05-19 2021-05-19 0000855683 MLSS:MrOsserViceChairmanOfBoardMember MLSS:EmploymentAgreementMember 2026-06-19 2026-06-19 0000855683 MLSS:MrOsserViceChairmanOfBoardMember MLSS:EmploymentAgreementMember 2026-04-01 2026-06-30 0000855683 MLSS:MrOsserViceChairmanOfBoardMember MLSS:EmploymentAgreementMember 2026-01-01 2026-06-30 0000855683 MLSS:MrOsserViceChairmanOfBoardMember MLSS:ConsultingAgreementMember 2026-04-01 2026-06-30 0000855683 MLSS:MrOsserViceChairmanOfBoardMember MLSS:ConsultingAgreementMember 2026-01-01 2026-06-30 0000855683 MLSS:MrOsserViceChairmanOfBoardMember MLSS:ConsultingAgreementMember 2025-04-01 2025-06-30 0000855683 MLSS:MrOsserViceChairmanOfBoardMember MLSS:ConsultingAgreementMember 2025-01-01 2025-06-30 0000855683 MLSS:MrOsserViceChairmanOfBoardMember 2026-06-30 0000855683 MLSS:MrOsserViceChairmanOfBoardMember 2026-01-01 2026-06-30 0000855683 MLSS:UniversityPainMedicineCenterSTEMMEEMember 2026-04-01 2026-06-30 0000855683 MLSS:UniversityPainMedicineCenterSTEMMEEMember 2026-01-01 2026-06-30 0000855683 MLSS:UniversityPainMedicineCenterSTEMMEEMember 2025-04-01 2025-06-30 0000855683 MLSS:UniversityPainMedicineCenterSTEMMEEMember 2025-01-01 2025-06-30 0000855683 MLSS:JanAdriaanArjanHaverhalsMember 2026-01-01 2026-06-30 0000855683 MLSS:JanAdriaanArjanHaverhalsMember 2025-01-01 2025-03-31 0000855683 MLSS:JanAdriaanArjanHaverhalsMember 2025-04-01 2025-06-30 0000855683 MLSS:JanAdriaanArjanHaverhalsMember 2025-10-01 2025-12-31 0000855683 MLSS:JanAdriaanArjanHaverhalsMember 2025-01-01 2025-06-30 0000855683 MLSS:ArjanJHaverhalsAndDirectorMember 2026-01-01 2026-06-30 0000855683 MLSS:ArjanJHaverhalsAndDirectorMember 2025-01-01 2025-12-31 0000855683 MLSS:MrHaverhalsConsultantAndDirectorMember 2026-01-01 2026-06-30 0000855683 MLSS:MrNealGoldmanMsBenedettaCasamentoAndDrDidierDemesminMember 2025-04-09 0000855683 MLSS:MrNealGoldmanMsBenedettaCasamentoAndDrDidierDemesminMember 2025-04-09 2025-04-09 0000855683 2026-04-20 0000855683 MLSS:MrNealGoldmanMember 2026-04-20 0000855683 MLSS:MsBenedettaCasamentoMember 2026-04-20 0000855683 MLSS:DrDidierDemesminMember 2026-04-20 0000855683 srt:MinimumMember 2026-07-24 0000855683 MLSS:InnovestSPAMember 2026-01-01 2026-06-30 0000855683 MLSS:InnovestSPAMember 2026-01-15 2026-01-15 0000855683 MLSS:BenedettaCasamentoMember 2026-06-24 2026-06-24 0000855683 MLSS:PurchaseCommitmentForDevicesMember 2026-01-01 2026-06-30 0000855683 MLSS:PurchaseCommitmentForDevicesMember 2026-06-30 0000855683 MLSS:PurchaseCommitmentForDevicesMember 2025-12-31 0000855683 MLSS:ContractsForFundingOfFutureEpiduralInstrumentsAndPartsMember 2026-06-30 0000855683 MLSS:ContractsForFundingOfFutureEpiduralInstrumentsAndPartsMember 2025-12-31 0000855683 us-gaap:SubsequentEventMember 2026-07-26 0000855683 us-gaap:SubsequentEventMember 2026-07-27 iso4217:USD shares iso4217:USD shares pure MLSS:Segment MLSS:Integer false --12-31 Q2 0000855683

10-Q true 2026-06-30 2026 false 001-14053 Milestone Scientific Inc. DE 13-3545623 425 Eagle Rock Avenue Suite 403 Roseland NJ 07068 973 535-2717 Common Stock, par value $.001 per share MLSS NYSEAMER Yes Yes Non-accelerated Filer true false false 88739185 0.001

2066770

1112642

10000

1003063

680620

9643

25548

9643

25548

40276

633953

468792

3086577

3781837

1276916

1408395

8117198

7477834

20127

19193

44857

79063

48977

55811

92489

150378

24150

8347798

7806429

1953844

1430250

907680

1359698

907680

1359698

956530

995206

225018

188406

225018

188406

218146

34170

27347

101883

130355

4397271

4131262

13668

27336

35208

465982

800000

4876921

4993806

0.001

125000000

88772518

88756989

80486449

80453116

88773

80487

139968127

137418974

-135674507

-133775322

33333

911516

3470877

2812623

8347798

7806429

2841038

2323466

5003071

4555886

930871

705860

1528880

1290845

1910167

1617606

3474191

3265041

2945532

3030952

5318184

6287680

6609

51789

6609

420909

19589

19496

39043

38936

2971730

3102237

5363836

6747525

-1061563

-1484631

-1889645

-3482484

2231

1521

-9540

4788

-1059332

-1483110

-1899185

-3477696

-1059332

-1483110

-1899185

-3477696

-0.01

-0.02

-0.04

93126415

82049984

87386906

81903323

80486449

80487

137418974

-133775322

-911516

2812623

256683

55479

-839853

80486449

80487

137731136

-134615175

-911516

2284932

254098

310606

311

99689

100000

6662962

6663

1513977

1520640

1300001

1300

295389

296689

12500 12 3738 3750 45100 45100

25000

-1059332

88772518

88773

139968127

-135674507

-911516

3470877

78047798

78048

134719274

-128053106

-911516

5832700

330787

293551 293551

182584

182

-182

-1994586

78230382

78230

135343430

-130047692

-911516

4462452

159679

207604

208

201043

201251

154494

154

-154

-1483110

78592480

78592

135703998

-131530802

-911516

3340272

-1899185

-3477696

4837

4026

34206

34910

566261

490465

145099 293551 28750 201251

4014

8525

57889

57356

326457

217350

-15905

6429

40276

-695260

183802

-131479 -143976 165161 72938

523594

429192

-452018

12142

-38676

-407536

-54894 25108

218146

56846 56808

-498285

-2772273

5771

5776

-5771

-5776

1797700

800000

332671

6845

5695

1458184

794305

954128

-1983744

1112642

3258058

2066770

1274314

350000

NOTE 1 — ORGANIZATION AND BUSINESS All references in this report to “Milestone Scientific,” “us,” “our,” “we,” the “Company” or “Milestone” refer to Milestone Scientific Inc., and its consolidated subsidiaries, Wand Dental, Inc., and Milestone Innovations Inc. and Milestone Education LLC (all described below), unless the context otherwise indicates. Milestone Scientific is the owner of the following registered U.S. trademarks: CompuDent®; CompuMed®; CompuFlo®; DPS Dynamic Pressure Sensing technology®; Milestone Scientific ®; the Milestone logo ®; SafetyWand®; STA Single Tooth Anesthesia System®; and The Wand ®. Milestone Scientific is a biomedical technology company that patents, designs, develops and commercializes innovative diagnostic and therapeutic injection technologies and devices for medical and dental use. Since our inception, we have engaged in pioneering proprietary, innovative, computer-controlled injection technologies, and solutions for the medical and dental markets. We believe our technologies are proven and well established. We have focused our resources on redefining the worldwide standard of care for injection techniques by making the experience more comfortable for the patient by reducing the anxiety and stress of receiving injections from the healthcare provider. Our computer-controlled injection devices make injections precise, efficient, and virtually painless. Milestone Scientific has developed a proprietary computer-controlled anesthetic delivery system based on our DPS Dynamic Pressure Sensing Technology® platform. The technology is designed to address the limitations of the traditional manual syringe by enabling precise, controlled delivery of anesthetic and other injectable drugs, as well as fluid aspiration. Our proprietary DPS technology regulates flow rate and continuously monitors pressure at the tip of the needle, providing healthcare practitioners with greater control during injections. The platform supports a range of dental and medical applications, including local anesthesia, subcutaneous drug delivery, and regional anesthesia procedures. In particular, the technology has specific medical applications in epidural procedures, where dynamic pressure sensing can assist healthcare practitioners in identifying the epidural space. DPS serves as Milestone Scientific’s core technology platform and provides the foundation for the development of next-generation drug delivery and injection devices. Our device, using The Wand®, a single use disposable handpiece, is marketed in dentistry under the trademark CompuDent®, and STA Single Tooth Anesthesia System® and is suitable for all dental procedures that require local anesthetic. The dental devices currently are sold in the United States, Canada and in over 33 other countries. Milestone Scientific also has 510(k) marketing clearance from the U.S. Food and Drug Administration (FDA) on the CompuFlo® Epidural Computer Controlled Anesthesia System in the lumbar, thoracic and cervical thoracic junction of the spine region. In addition, Milestone Scientific has obtained CE mark approval and can be marketed and sold in most European countries. Our recent receipt of technology-specific CPT Code for the Company’s technology by the American Medical Association marks an important milestone that could increase the potential number of anesthesia pain management clinics adopting the CompuFlo instrument. A CPT code expands the potential for reimbursement of epidural procedures in pain management utilizing the CompuFlo Epidural System., which we believe should help accelerate the commercial roll-out of CompuFlo in the United States.

NOTE 2 — GOING CONCERN AND LIQUIDITY Our financial statements have been prepared in conformity with generally accepted accounting principles, which contemplate continuation of the Company on a going concern basis. The going concern basis assumes that assets are realized, and liabilities are extinguished in the ordinary course of business at amounts disclosed in the financial statements. The Company has incurred total losses since its inception of $135.7 million. The Company’s operating losses were approximately $1.1 and $1.9 million for the three and six months ended June 30, 2026. On June 30, 2026, Milestone Scientific had cash and cash equivalents of approximately $2.1 million and working capital of approximately $3.7 million. For the six months ended June 30, 2026, we had cash flows used in operating activities of approximately $498,000. These conditions raise substantial doubt about the Company’s ability to continue as a going concern. On April 20, 2026, the Company completed a private placement of 7,962,963 units of common stock and warrants to purchase common stock at a purchase price of $0.27 per unit, generating net proceeds of approximately $1.81 million, consisting of cash and a reduction in outstanding principal and accrued interest of the Company’s outstanding convertible notes, the holders of which applied such principal amounts toward the purchase of units in the offering in lieu of cash (the “Private Placement”). Each warrant entitles the holder to purchase one share of common stock at an exercise price of $<span id="xdx_90A_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_c20260420__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zXvKGwIdxrUe" title="Warrant exercise price">0.3375 per share and is exercisable for a period of three years. If exercised in full, the warrants could provide up to approximately $2.69 million in additional gross proceeds; however, there can be no assurance that any or all of the warrants will be exercised. The Company’s recurring losses from operations, negative cash flows, and accumulated deficit raise substantial doubt about its ability to continue as a going concern. The completion of the private placement in April 2026 has improved the Company’s liquidity position; however, the Company’s ability to continue as a going concern is dependent upon its ability to generate sufficient revenue, manage operating expenses, and, if necessary, obtain additional financing.

-135700000

-1100000

-1900000

2100000

3700000

-498000

7962963

0.27

1810000

0.3375

2690000

NOTE 3 — SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES 1. Basis of Presentation The accompanying unaudited condensed consolidated financial statements of Milestone Scientific Inc. have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all the information and disclosures required by GAAP for complete annual financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the Company’s financial position and results of operations for the interim periods presented. Interim results are not necessarily indicative of the results that may be expected for the full year or any subsequent period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes for the year ended December 31, 2025, included in the Company’s Annual Report on Form 10-K. 2. Basic and Diluted Net Loss Per Common Share Milestone Scientific presents “basic” earnings (loss) per common share and, if applicable, “diluted” earnings (loss) per common share applicable to common stockholders pursuant to the provisions of ASC 260, “Earnings per Share”. Basic earnings (loss) per common share is calculated by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding and to be issued common shares as follows: 93,126,415 and 87,386,906 for the three and six months ended June 30, 2026 and 82,049,984 and 81,903,323 for the three and six months ended June 30, 2025, respectively. The calculation of diluted earnings per common share is like that of basic earnings per common share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if all potentially dilutive common shares, such as those issuable upon the exercise of stock options and warrants, were issued during the period. Since Milestone Scientific had net losses in the three and six months ended June 30, 2026, and 2025, the assumed effects of the exercise of potentially dilutive outstanding stock options, unissued restricted stock awards (“RSA”), unconverted convertible notes and warrants were not included in the calculation as their effect would have been anti-dilutive. Such outstanding options, RSA’s unconverted convertible notes, and warrants totaled 15,302,498 and 3,792,211 for the three and six months ended June 30, 2026 and 2025, respectively. 3. Recent Accounting Pronouncements Recently Issued Accounting Pronouncement In November 2024, the Financial Accounting Standards Board, “FASB”, issued Accounting Standards Update “ASU” 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40), to improve the disaggregation of expenses within the consolidated statement of operations. The amendments in ASU 2024-03 require disclosures, in the notes to the consolidated financial statements, specified information about certain costs and expenses. The amendments require that at each interim and annual reporting period an entity disclose (a) employee compensation, (b) depreciation, and (c) intangible asset amortization included in each relevant expense caption; include certain amounts that are already required to be disclosed under current generally accepted accounting principles (GAAP) in the same disclosure as the other disaggregation requirements; and disclose a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively. The amendments in ASU 2024-03 are effective January 1, 2027, and effective for interim periods beginning January 1, 2028. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company will evaluate the impact of ASU 2024-03 on its financial statements. 4. Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) ASC 480, “Distinguishing Liabilities from Equity” (“ASC 480”) and ASC 815, “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, whether they meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations. Management concluded that its warrants qualify for equity accounting treatment.

1. Basis of Presentation The accompanying unaudited condensed consolidated financial statements of Milestone Scientific Inc. have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) for interim financial information and the instructions to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all the information and disclosures required by GAAP for complete annual financial statements. In the opinion of management, the accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, necessary for a fair presentation of the Company’s financial position and results of operations for the interim periods presented. Interim results are not necessarily indicative of the results that may be expected for the full year or any subsequent period. These unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial statements and related notes for the year ended December 31, 2025, included in the Company’s Annual Report on Form 10-K.

2. Basic and Diluted Net Loss Per Common Share Milestone Scientific presents “basic” earnings (loss) per common share and, if applicable, “diluted” earnings (loss) per common share applicable to common stockholders pursuant to the provisions of ASC 260, “Earnings per Share”. Basic earnings (loss) per common share is calculated by dividing net income or loss applicable to common stockholders by the weighted average number of common shares outstanding and to be issued common shares as follows: 93,126,415 and 87,386,906 for the three and six months ended June 30, 2026 and 82,049,984 and 81,903,323 for the three and six months ended June 30, 2025, respectively. The calculation of diluted earnings per common share is like that of basic earnings per common share, except that the denominator is increased to include the number of additional common shares that would have been outstanding if all potentially dilutive common shares, such as those issuable upon the exercise of stock options and warrants, were issued during the period. Since Milestone Scientific had net losses in the three and six months ended June 30, 2026, and 2025, the assumed effects of the exercise of potentially dilutive outstanding stock options, unissued restricted stock awards (“RSA”), unconverted convertible notes and warrants were not included in the calculation as their effect would have been anti-dilutive. Such outstanding options, RSA’s unconverted convertible notes, and warrants totaled 15,302,498 and 3,792,211 for the three and six months ended June 30, 2026 and 2025, respectively.

93126415

87386906

82049984

81903323

15302498

3792211

3. Recent Accounting Pronouncements Recently Issued Accounting Pronouncement In November 2024, the Financial Accounting Standards Board, “FASB”, issued Accounting Standards Update “ASU” 2024-03, Income Statement—Reporting Comprehensive Income—Expense Disaggregation Disclosures (Subtopic 220-40), to improve the disaggregation of expenses within the consolidated statement of operations. The amendments in ASU 2024-03 require disclosures, in the notes to the consolidated financial statements, specified information about certain costs and expenses. The amendments require that at each interim and annual reporting period an entity disclose (a) employee compensation, (b) depreciation, and (c) intangible asset amortization included in each relevant expense caption; include certain amounts that are already required to be disclosed under current generally accepted accounting principles (GAAP) in the same disclosure as the other disaggregation requirements; and disclose a qualitative description of the amounts remaining in relevant expense captions that are not separately disaggregated quantitatively. The amendments in ASU 2024-03 are effective January 1, 2027, and effective for interim periods beginning January 1, 2028. Early adoption is permitted for annual financial statements that have not yet been issued or made available for issuance. The Company will evaluate the impact of ASU 2024-03 on its financial statements.

4. Warrants The Company accounts for warrants as either equity-classified or liability-classified instruments based on an assessment of the warrant’s specific terms and applicable authoritative guidance in Financial Accounting Standards Board (“FASB”) ASC 480, “Distinguishing Liabilities from Equity” (“ASC 480”) and ASC 815, “Derivatives and Hedging” (“ASC 815”). The assessment considers whether the warrants are freestanding financial instruments pursuant to ASC 480, whether they meet the definition of a liability pursuant to ASC 480, and whether the warrants meet all of the requirements for equity classification under ASC 815, including whether the warrants are indexed to the Company’s own common stock and whether the warrant holders could potentially require “net cash settlement” in a circumstance outside of the Company’s control, among other conditions for equity classification. This assessment, which requires the use of professional judgment, is conducted at the time of warrant issuance and as of each subsequent quarterly period end date while the warrants are outstanding. For issued or modified warrants that meet all of the criteria for equity classification, the warrants are required to be recorded as a component of equity at the time of issuance. For issued or modified warrants that do not meet all the criteria for equity classification, the warrants are required to be recorded as liabilities at their initial fair value on the date of issuance, and each balance sheet date thereafter. Changes in the estimated fair value of the warrants are recognized as a non-cash gain or loss on the statements of operations. Management concluded that its warrants qualify for equity accounting treatment.

NOTE 4 — INVENTORIES, NET Inventories consist of the following: SCHEDULE OF INVENTORIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20260630_z6OxBw400YT4" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20251231_zjlkovhswq37" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_408_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_hus-gaap--PublicUtilitiesInventoryAxis__custom--DentalFinishedGoodsMember_z39pAOXl0WQ2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Dental finished goods</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,914,209</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,598,270</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_hus-gaap--PublicUtilitiesInventoryAxis__custom--MedicalFinishedGoodsMember_zUhXbUxNy0q5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Medical finished goods</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">81,511</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">108,975</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_hus-gaap--PublicUtilitiesInventoryAxis__custom--MedicalFinishedGoodsMember_zrbCpcKzSGG" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Inventory finished goods</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">81,511</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">108,975</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InventoryPartsAndComponentsNetOfReserves_iI_zC6l2iDWbCG8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Component parts and other materials</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">90,857</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">74,592</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InventoryNet_iI_zfUtCoDdCnK5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total inventories</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,086,577</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,781,837</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> The Company had an allowance on slow moving Medical finished goods due to the slow adoption of the epidural instruments and handpieces for approximately $504,000 and $1.1 million as of June 30, 2026, and December 31, 2025, respectively. The decrease in the allowance was primarily attributable to the disposal of fully reserved inventory and resulted in an immaterial impact on the Company’s results of operations for the period.

Inventories consist of the following: SCHEDULE OF INVENTORIES <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20260630_z6OxBw400YT4" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_499_20251231_zjlkovhswq37" style="border-bottom: Black 1pt solid; text-align: center">December 31, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_408_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_hus-gaap--PublicUtilitiesInventoryAxis__custom--DentalFinishedGoodsMember_z39pAOXl0WQ2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Dental finished goods</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">2,914,209</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 16%; text-align: right">3,598,270</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_hus-gaap--PublicUtilitiesInventoryAxis__custom--MedicalFinishedGoodsMember_zUhXbUxNy0q5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Medical finished goods</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">81,511</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">108,975</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_hus-gaap--PublicUtilitiesInventoryAxis__custom--MedicalFinishedGoodsMember_zrbCpcKzSGG" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left">Inventory finished goods</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">81,511</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">108,975</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--InventoryPartsAndComponentsNetOfReserves_iI_zC6l2iDWbCG8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Component parts and other materials</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">90,857</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">74,592</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_407_eus-gaap--InventoryNet_iI_zfUtCoDdCnK5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Total inventories</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,086,577</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left">$</td><td style="border-bottom: Black 2.5pt double; text-align: right">3,781,837</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

2914209

3598270

81511

108975

81511

108975

90857

74592

3086577

3781837

504000

1100000

NOTE 5 — ADVANCES ON CONTRACTS The advances on contracts represent funding for future Single Tooth Anesthesia System® (STA) devices, epidural instruments, and epidural replacement parts. The balance of the advances as of June 30, 2026 and December 31, 2025, is approximately $1.3 and $1.4 million, respectively. The advance is classified as current based on the estimated annual usage of the underlying inventory.

1300000

1400000

NOTE 6— STOCKHOLDERS’ EQUITY WARRANTS On April 20, 2026, Company entered into a securities purchase agreement (the “Purchase Agreement”) with the purchasers named therein (the “Purchasers”), for the private placement (the “Private Placement”) of an aggregate of 7,962,963 units (the “Units”), with each Unit consisting of (i) one share of the Company’s common stock, par value $0.001 per share (the “Common Stock”), and (ii) one warrant to purchase one share of Common Stock (each, a “Warrant”). The purchase price paid by the Purchasers for each Unit was $0.27 (the “Per Unit Purchase Price”). Certain directors and officers participated in the Private Placement, purchasing an aggregate of $150,000 of Units for cash and converting into Units a total of $<span id="xdx_902_eus-gaap--StockIssuedDuringPeriodValueConversionOfConvertibleSecurities_c20260420__20260420__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_zwefIlhKAVSj" title="Warrant conversion">351,000 in respect of convertible notes evidencing loans they made to the Company in 2025, in each case at the same price and (except for such conversion of loans) on the same terms as all other securities offered in the Private Placement. Each Warrant has an exercise price equal to 125% of the Per Unit Purchase Price per share, or $<span id="xdx_90E_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_c20260420__us-gaap--SubsidiarySaleOfStockAxis__us-gaap--PrivatePlacementMember_z5CXsvJl5ixl" title="Warrant exercise price pershare">0.3375 per warrant share, and will be exercisable after six (6) months from the closing and prior to the third anniversary of the closing for cash only. As of June 30, 2026, outstanding warrants were 7,962,962. The following table summarizes information about Warrants for the six month periods ending June 30, 2026. SCHEDULE OF INFORMATION ABOUT SHARES ISSUABLE UNDER WARRANTS OUTSTANDING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Averaged Exercise Price $</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Life</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Options Value $</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Warrants outstanding at January 1, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20260101__20260630_zGLOqbRzqKE6" style="text-align: right" title="Warrant shares outstanding, Beginning">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20260101__20260630_zAhMR7y6PT44" style="text-align: right" title="Weighted Average exercise price, Beginning">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_iS_c20260101__20260630_z722bTDHtTFf" style="text-align: right" title="Intrinsic value, Beginning">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; width: 40%; text-align: left">Granted during 2026</td><td style="padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20260101__20260630_z2XZSJ0hhF5a" style="border-bottom: Black 1pt solid; width: 11%; text-align: right" title="Warrant shares, Granted">7,962,963</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20260101__20260630_zkyuES0mvPL7" style="border-bottom: Black 1pt solid; width: 11%; text-align: right" title="Weighted Average exercise price, Granted">0.3375</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"></td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingGramtedWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630_zpzFEkB5g51i" title="Weighted Average remaining life, Granted">3.00</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValueGranted_iS_c20260101__20260630_zJDqu7cQqw8" style="border-bottom: Black 1pt solid; width: 11%; text-align: right" title="Intrinsic value, Granted">-</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Warrants outstanding June 30, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20260101__20260630_zCfhOnFL6MPl" style="text-align: right" title="Warrant shares outstanding and exercisable, Ending">7,962,963</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20260101__20260630_zwI0d3hshQx3" style="text-align: right" title="Weighted Average exercise price, Ending">0.3375</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td style="text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630_z73CdkmoNpEa" title="Weighted Average remaining life, ending">2.81</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_iE_c20260101__20260630_zu1rb0IZ5Zih" style="text-align: right" title="Intrinsic value, Ending"> -</td><td style="text-align: left"> </td></tr> </table> SHARES TO BE ISSUED As of June 30, 2026, and 2025, there were <span id="xdx_90B_eus-gaap--DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_iI_c20260630__srt--TitleOfIndividualAxis__custom--OfficersDirectorsAndOtherEmployeesMember_zmMEUnPaEz72" title="Shares to be issued">3,596,260 and <span id="xdx_902_eus-gaap--DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_iI_c20250630__srt--TitleOfIndividualAxis__custom--OfficersDirectorsAndOtherEmployeesMember_zHnxQqWS6uqd" title="Shares to be issued">3,076,871 shares to be issued, respectively, whose issuance has been deferred under the terms of employment and consulting agreements with officers and directors and other employees of Milestone Scientific. Such shares will be issued to each party upon termination of their employment or other relationship with the Company. As of June 30, 2026 and 2025 there were <span id="xdx_90C_eus-gaap--DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_iI_c20260630__srt--TitleOfIndividualAxis__custom--NonemployeesMember_ztoOJuYGRV58" title="Shares to be issued">1,088,369 and <span id="xdx_90A_eus-gaap--DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_iI_c20250630__srt--TitleOfIndividualAxis__custom--NonemployeesMember_zpdSfqZgbCw7" title="Shares to be issued">631,792 respectively, shares to be issued to non-employees for services rendered. The number of shares was fixed by contract prior to the date of grant, subject to performance, and were fully earned upon the grant date. Such shares will be issued to each party upon termination of their relationship with the Company. <p id="xdx_89F_ecustom--DeferredCompensationArrangementWithIndividualSharebasedPaymentsTableTextBlock_z8DbzdtoC00k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes information about shares to be issued for the six month periods ending June 30, 2026 and 2025. SCHEDULE OF SHARES TO BE ISSUED <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20260101__20260630_zjSxsilMkoq4" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20250101__20250630_zYfS03nGlEt7" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_404_eus-gaap--DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_iS_z6kPsRDU1Lse" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Shares-to-be-issued, outstanding January 1, 2026 and 2025, respectively</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">4,449,403</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">3,393,017</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_iS_zBcHsczxUcV3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Shares-to-be-issued, outstanding beginning balance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,449,403</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,393,017</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--DeferredCompensationArrangementWithIndividualSharesGranted_zVsnBf166Bh3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Granted in current period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">405,682</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">315,646</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredCompensationArrangementWithIndividualSharesIssued_iN_di_zTpzkNh4nKR2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Issued in current period</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(170,455</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_iE_zGtrdPcotmTa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Shares-to be issued outstanding June 30, 2026 and 2025, respectively</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">4,684,630</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">3,708,663</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_iE_zMTBUje2YYH5" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Shares-to be issued outstanding ending balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">4,684,630</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">3,708,663</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

7962963

0.001

0.27

150000

351000

1.25

0.3375

The following table summarizes information about Warrants for the six month periods ending June 30, 2026. SCHEDULE OF INFORMATION ABOUT SHARES ISSUABLE UNDER WARRANTS OUTSTANDING <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Warrants</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Averaged Exercise Price $</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Life</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Options Value $</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Warrants outstanding at January 1, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iS_c20260101__20260630_zGLOqbRzqKE6" style="text-align: right" title="Warrant shares outstanding, Beginning">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iS_c20260101__20260630_zAhMR7y6PT44" style="text-align: right" title="Weighted Average exercise price, Beginning">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_iS_c20260101__20260630_z722bTDHtTFf" style="text-align: right" title="Intrinsic value, Beginning">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 1pt; width: 40%; text-align: left">Granted during 2026</td><td style="padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGranted_c20260101__20260630_z2XZSJ0hhF5a" style="border-bottom: Black 1pt solid; width: 11%; text-align: right" title="Warrant shares, Granted">7,962,963</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsGrantsInPeriodWeightedAverageExercisePrice_c20260101__20260630_zkyuES0mvPL7" style="border-bottom: Black 1pt solid; width: 11%; text-align: right" title="Weighted Average exercise price, Granted">0.3375</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"></td><td style="border-bottom: Black 1pt solid; width: 11%; text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingGramtedWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630_zpzFEkB5g51i" title="Weighted Average remaining life, Granted">3.00</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td><td style="padding-bottom: 1pt; width: 2%"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValueGranted_iS_c20260101__20260630_zJDqu7cQqw8" style="border-bottom: Black 1pt solid; width: 11%; text-align: right" title="Intrinsic value, Granted">-</td><td style="padding-bottom: 1pt; width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Warrants outstanding June 30, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingNumber_iE_c20260101__20260630_zCfhOnFL6MPl" style="text-align: right" title="Warrant shares outstanding and exercisable, Ending">7,962,963</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left">$</td><td id="xdx_981_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageExercisePrice_iE_c20260101__20260630_zwI0d3hshQx3" style="text-align: right" title="Weighted Average exercise price, Ending">0.3375</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"></td><td style="text-align: right"><span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardNonOptionEquityInstrumentsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630_z73CdkmoNpEa" title="Weighted Average remaining life, ending">2.81</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_983_ecustom--ShareBasedCompensationArrangementByShareBasedPaymentAwardNonOptionEquityInstrumentsOutstandingIntrinsicValue_iE_c20260101__20260630_zu1rb0IZ5Zih" style="text-align: right" title="Intrinsic value, Ending"> -</td><td style="text-align: left"> </td></tr> </table>

7962963

0.3375 P3Y

7962963

0.3375 P2Y9M21D

3596260

3076871

1088369

631792

<p id="xdx_89F_ecustom--DeferredCompensationArrangementWithIndividualSharebasedPaymentsTableTextBlock_z8DbzdtoC00k" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">The following table summarizes information about shares to be issued for the six month periods ending June 30, 2026 and 2025. SCHEDULE OF SHARES TO BE ISSUED <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20260101__20260630_zjSxsilMkoq4" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20250101__20250630_zYfS03nGlEt7" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td> </td> <td colspan="2"> </td><td> </td><td> </td> <td colspan="2"> </td><td> </td></tr> <tr id="xdx_404_eus-gaap--DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_iS_z6kPsRDU1Lse" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 60%; text-align: left">Shares-to-be-issued, outstanding January 1, 2026 and 2025, respectively</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">4,449,403</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 16%; text-align: right">3,393,017</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_402_eus-gaap--DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_iS_zBcHsczxUcV3" style="display: none; vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Shares-to-be-issued, outstanding beginning balance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,449,403</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,393,017</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_ecustom--DeferredCompensationArrangementWithIndividualSharesGranted_zVsnBf166Bh3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Granted in current period</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">405,682</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">315,646</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--DeferredCompensationArrangementWithIndividualSharesIssued_iN_di_zTpzkNh4nKR2" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Issued in current period</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">(170,455</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_iE_zGtrdPcotmTa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Shares-to be issued outstanding June 30, 2026 and 2025, respectively</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">4,684,630</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">3,708,663</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--DeferredCompensationArrangementWithIndividualSharesAuthorizedForIssuance_iE_zMTBUje2YYH5" style="display: none; vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 2.5pt">Shares-to be issued outstanding ending balance</td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">4,684,630</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td style="border-bottom: Black 2.5pt double; text-align: right">3,708,663</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

4449403

3393017

4449403

3393017

405682 315646

170455

4684630

3708663

4684630

3708663

NOTE 7 — STOCK OPTION PLANS The Milestone Scientific Inc., Amended and Restated 2020 Equity Incentive Plan (the “2020 Plan”) provides for awards of restricted common stock, restricted stock units, options to purchase shares and other awards. At June 30, 2026, the maximum number of shares that could be issued thereunder was <span id="xdx_90F_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260630__20260630__us-gaap--PlanNameAxis__custom--TwentyTwentyEquityIncentivePlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember_zQD6WJXMP4Vc" title="Number of shares issued">11,500,000 shares of common stock., On July 27, 2026, the stockholders of the Company amended the 2020 Plan to increase the maximum number of shares that can be issued thereunder to <span id="xdx_904_eus-gaap--StockIssuedDuringPeriodSharesNewIssues_c20260727__20260727__us-gaap--PlanNameAxis__custom--TwentyTwentyEquityIncentivePlanMember__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--RangeAxis__srt--MaximumMember__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zi88er8mYlN8" title="Number of shares issued">28,750,000 shares of common stock. The plan expires in June 2031. Options may be granted to employees, directors, and consultants of Milestone Scientific for the purchase of shares of common stock at a price not less than the fair market value of common stock on the date of grant. Generally, options become exercisable over a <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20230628__20230628__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z6X7Ih5AFvag" title="Exercisable period">3-year period from the grant date and expire <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dtY_c20230628__20230628__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zEUigd8OpZl" title="Expire term">5 years after the date of grant. Additionally on April 30, 2026, the Compensation Committee recommended the grant of performance-based restricted stock units (“PRSUs”) to certain officers of the Company. As all of the PRSUs are to have the same performance milestones and other terms and conditions (other than the actual grant amounts), the Compensation Committee established a sub-plan of the 2020 Plan (the “Sub-Plan”) as the framework together with the 2020 Plan for the award of PRSUs (each, an “Award” and collectively, “Awards”), with a fixed pool of PRSUs. The total aggregate number of shares of common stock that to be issued under 2020 Plan will be adjusted to 28,734,635, an increase of <span id="xdx_90E_eus-gaap--StockIssuedDuringPeriodSharesPeriodIncreaseDecrease_c20260430__20260430__us-gaap--PlanNameAxis__custom--TwoThousandTwentyPlanMember_zJV8CsgpLTSk" title="Increase in shares issued">17,234,635 shares as a result of the approval of the Sub-Plan (the “Aggregate Pool”). The recommendation of the award of PRSUs under the Sub-Plan was subject to stockholder approval to increase the number of shares covered by the 2020 Plan to account for the recommendation to issue PRSU awards under the Sub-Plan, which increase was approved by the stockholders at the Company’s Annual Meeting on July 27, 2026 as aforesaid. On April 30, 2026 (the “Effective Date”), the Compensation Committee of the Board of Directors (the “Compensation Committee”) of the Company approved a one-time stock option exchange program (the “Exchange Program”) for outstanding stock options granted under the Company’s 2020 Plan and the applicable award agreements thereunder, held by Eric Hines, the President and Chief Executive Officer, and Jason Papes, the Senior Vice President, Global Head of Sales and Marketing, of the Company (“Eligible Options”), all of which have exercise prices that exceed the current fair market value of the Company’s common stock (the “Common Stock”). The Exchange Program was undertaken in accordance with, and as expressly permitted by, the 2020 Plan and the applicable award agreements thereunder, and provides that such eligible participants may voluntarily elect to surrender some or all of their Eligible Options in exchange for newly granted stock options to purchase shares of the Company’s Common Stock, at an exercise price reduced to $<span id="xdx_900_eus-gaap--SharebasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeExercisableOptionsWeightedAverageExercisePrice1_iI_pid_c20260430_zdgsHB5xTRaa" title="Stock option exercise price">0.27 per share (the “Reduced Exercise Price, which exercise price equals the closing price of the Company’s Common Stock on the Effective Date (the “Repricing”). All of the Eligible Options (i) were granted under the 2020 Plan, (ii) as of the Effective Date, were held by continuing employees, (iii) had not previously been repriced and (iv) had an exercise price per share greater than the Reduced Exercise Price (the “Repriced Options”). The Repriced Options have the same vesting commencement date and expiration date as the respective Eligible Options surrendered. In addition, for each Repriced Option, the vesting schedule was modified such that the number of shares vesting on the applicable vesting commencement date was increased from <span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20260430__20260430__srt--RangeAxis__srt--MinimumMember_zdXs3697aoC8" title="Number of shares vesting">200,000 to <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedNumberOfShares_pid_c20260430__20260430__srt--RangeAxis__srt--MaximumMember_z94wMLcjuS91" title="Number of shares vesting">500,000 shares, constituting twenty-five percent (25%) of the total number of shares subject to the Repriced Option, and providing for the vesting of the remainder of the shares subject to the Repriced Options in two equal tranches of 750,000 shares on the first and second anniversaries of the applicable vesting commencement date rather than over three years from the vesting commencement date, subject to the continued employment of the grantee on the applicable vesting date and compliance with certain restrictive covenants. No other changes were made to the Repriced Options as a result of the Repricing. The number of shares of Common Stock issuable upon the exercise of each of the Repriced Options (<span id="xdx_902_ecustom--StockIssuedDuringPeriodSharesStockRepricedOptionsExercised_pn5n6_c20260430__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zdiAVCLeqfP4" title="Number of repriced option exercised">2.0 million shares), and the total number of shares underlying all Repriced Options (<span id="xdx_903_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardRepricedOptionsVestedNumberOfShares_pn5n6_c20260430__20260430__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zQhMR8mEQrdb" title="Number of repriced option">4.0 million shares), remains the same number of shares as underlying the respective Eligible Options surrendered, in accordance with the 2020 Plan. The Eligible Options previously had exercise prices ranging from $0.46 to $0.50 per share and were granted in August 2025. The Company accounted for each Repriced Option as a modification under ASC 718, Compensation—Stock Compensation, and the Company measured the fair value of the modified awards immediately before and immediately after the modification using the Black-Scholes-Merton option-pricing model. The Company estimated the fair value of the Repriced Options immediately before the Effective Date using the Black-Scholes option pricing model with the following assumptions: a risk-free interest rate of <span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zORtqiMf99dg" title="Risk free interest rate">3.86%, expected volatility of <span id="xdx_901_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zPNohHNOOlQg" title="Expected volatility rate">82.3% (based on the Company’s historical volatility over the expected term), an expected term of <span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zfAkOyXMli29" title="Expected term">5.2 years, a dividend yield of <span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember_zAUtnBbokROf" title="Dividend yield rate">0%, and a stock price ranging from $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_dtY_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MinimumMember_zga4QAw0GAb4" title="Exercise price">0.45 to $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_dtY_c20260630__us-gaap--AwardTypeAxis__us-gaap--StockOptionMember__srt--RangeAxis__srt--MaximumMember_zRXKN4NJGSrc" title="Exercise price">0.50. The Company estimated the fair value of the Repriced Options immediately after the Effective Date using the Black-Scholes option pricing model with the following assumptions: a risk-free interest rate of <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_dp_c20260101__20260630__us-gaap--AwardTypeAxis__custom--StockOptionOneMember_z04RFYvP46Nh" title="Risk free interest rate">1.75%, expected volatility of <span id="xdx_906_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate_dp_c20260101__20260630__us-gaap--AwardTypeAxis__custom--StockOptionOneMember_z9ofb8olnMr2" title="Expected volatility rate">86.6% (based on the Company’s historical volatility over the expected term), an expected term of <span id="xdx_909_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__custom--StockOptionOneMember_zGVFJzhw1IL3" title="Expected term">5.7 years, a dividend yield of <span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate_dp_c20260101__20260630__us-gaap--AwardTypeAxis__custom--StockOptionOneMember_zX6v9xB8hSLe" title="Dividend yield rate">0%, and a stock price of $<span id="xdx_902_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice_iI_dtY_c20260630__us-gaap--AwardTypeAxis__custom--StockOptionOneMember_zBp5rmYsp8wf" title="Exercise price">0.27. As a result of the measurement of the modified awards immediately before and after the modification date, the Company determined an incremental fair value of $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c20260101__20260630_zkbLZEzBtzpi" title="Share based compensation fair value">146,000 related to the modified awards. This incremental fair value of $<span id="xdx_90E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodTotalFairValue_c20260101__20260630_zcGJr4nkR4n5" title="Share based compensation fair value">146,000 is being recognized as compensation expense over the remaining requisite service period of the replacement awards. Any unrecognized compensation cost associated with the original, canceled awards continues to be amortized over the original vesting periods. Milestone Scientific recognizes compensation expenses over the requisite service period and in the case of performance-based options over the period of the expected performance. For the three and six months ended June 30, 2026, Milestone Scientific recognized approximately $239,000 and $496,000 of total employee compensation cost, respectively, recorded in general and administrative expenses on the statement of operations. For the three and six months ended June 30, 2025, Milestone Scientific recognized approximately $158,000 and $329,000 of total employee compensation cost, respectively, recorded in general and administrative expenses on the statement of operations. As of June 30,2026, there was approximately $<span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_iI_pn5n6_c20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zw8tiHEAN2r6">943,000 of total unrecognized compensation cost related to non-vested options. Milestone Scientific expects to recognize these costs over a weighted average period of <span id="xdx_901_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z5HybkcGnwD6">2.1 years. <p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zYGU9LGcd622" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">A summary of option activity for employees under the plans and changes during the six months ended June 30, 2026 is presented below: SCHEDULE OF STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Averaged Exercise Price $</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Options Value $</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">Options outstanding at January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zyk2NQbQvSdf" style="width: 10%; text-align: right" title="Number of Options Outstanding, Beginning Balance">6,032,175</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z1xb6OiCXabd" style="width: 10%; text-align: right" title="Weighted Averaged Exercise Price, Beginning Balance">1.15</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zFS13mxXtcG" title="Weighted Average Remaining Contractual Life (Years), Outstanding">8.13</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zV5mTsN9deO1" style="width: 10%; text-align: right" title="Aggregate Intrinsic Options Value, Beginning Balance">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Granted during 2026(1)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_fKDEp_zW2aYaF7Ceal" style="text-align: right" title="Number of Options, Granted">4,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_fKDEp_zYBNUNwlh1P5" style="text-align: right" title="Weighted Averaged Exercise Price, Granted">0.27</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Forfeited or expired during 2026(1)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_fKDEp_z9AQz2gEC4M3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited or expired">(4,032,175</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_fKDEp_znVzof4SY6x4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Averaged Exercise Price, Forfeited or expired">0.50</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Options outstanding June 30, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z5z97h5RWBy9" style="text-align: right" title="Number of Options Outstanding, Ending Balance">6,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7Li7cyIK9Il" style="text-align: right" title="Weighted Averaged Exercise Price, Ending Balance">1.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zSKAsc3IgfOe" title="Weighted Average Remaining Contractual Life (Years), Outstanding">8.15</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUx8mwvpB4l5" style="text-align: right" title="Aggregate Intrinsic Options Value, Ending Balance">200,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable, June 30, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zc4PgamxMiB5" style="text-align: right" title="Number of Options, Exercisable">3,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zNyvQWjSy4K" style="text-align: right" title="Weighted Averaged Exercise Price, Exercisable">1.73</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrgKdsEHZlM7" title="Weighted Average Remaining Contractual Life (Years), Exercisable">6.48</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_ze0Nh25ZgR6a" style="text-align: right" title="Aggregate Intrinsic Options Value, Exercisable">50,000</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">(1)</td><td style="text-align: justify">Includes <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFU1RSSUNURUQgU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zFq07WQmWjGa" title="Number of Options, Granted">4,000,000 stock options exchanged pursuant to the Exchange Program</td> </tr></table> <p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zqdjKVTcjUr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">A summary of option activity for non-employees under the plans and changes during the six months ended June 30, 2026 is presented below: SCHEDULE OF STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Averaged Exercise Price $</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Options Value $</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">Options outstanding at January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zf6SPakLInJg" style="width: 10%; text-align: right" title="Number of Options Outstanding, Beginning Balance">83,330</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zNUGUyJzxdO7" style="width: 10%; text-align: right" title="Weighted Averaged Exercise Price, Beginning Balance">1.59</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zeOa6Ye2eULc" title="Weighted Average Remaining Contractual Life (Years), Outstanding">2.40</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zOXdeQgaoUe" style="width: 10%; text-align: right" title="Aggregate Intrinsic Options Value, Beginning Balance">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Forfeited or expired during 2026</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zP0xR55oUgsa" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited or expired">(16,666</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zaVa9Bjqvet1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Averaged Exercise Price, Forfeited or expired">3.94</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Options outstanding June 30, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zjaN3xlLaZ88" style="text-align: right" title="Number of Options Outstanding, Ending Balance">66,664</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zBasuL63Gg82" style="text-align: right" title="Weighted Averaged Exercise Price, Ending Balance">1.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zVqjwuIMIXNd" title="Weighted Average Remaining Contractual Life (Years), Outstanding">2.45</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z5a8S4NzI9Le" style="text-align: right" title="Aggregate Intrinsic Options Value, Ending Balance">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercisable, June 30, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zEdaZIEoqIcd" style="text-align: right" title="Number of Options, Exercisable">49,994</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zGOTQLoUd67g" style="text-align: right" title="Weighted Averaged Exercise Price, Exercisable">1.02</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zjgC62RGUAEa" title="Weighted Average Remaining Contractual Life (Years), Exercisable">2.10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zubPFX0aVbv3" style="text-align: right" title="Aggregate Intrinsic Options Value, Exercisable">-</td><td style="text-align: left"> </td></tr> </table> For the three and six months ended June 30, 2026 Milestone Scientific recognized approximately $<span id="xdx_907_eus-gaap--AllocatedShareBasedCompensationExpense_c20260401__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zD4tsGke37Zc" title="Stock compensation expense">1,200 and $<span id="xdx_90F_eus-gaap--AllocatedShareBasedCompensationExpense_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z919XwFnB4Xh" title="Stock compensation expense">2,400 expense related to non-employee options, respectively. For the three and six months ended June 30, 2025 Milestone Scientific recognized approximately $<span id="xdx_905_eus-gaap--AllocatedShareBasedCompensationExpense_c20250401__20250630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zI1Os1dp3tKj" title="Stock compensation expense">1,400 and $<span id="xdx_904_eus-gaap--AllocatedShareBasedCompensationExpense_c20250101__20250630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zOVDdJUL9Pzf" title="Stock compensation expense">8,000 expense related to non-employee options, respectively. A summary of restricted stock under the plans and changes during the six months ended June 30, 2026 is presented below: <p id="xdx_898_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zvSs19QEAlh6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> SCHEDULE OF RESTRICTED STOCK <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Grant-Date Fair Value per Award</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Non-vested as January 1, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zuQ42Qh1Nmki" style="text-align: right" title="Number of Shares, Non-vested Beginning Balance">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zRJJvWOIu7Sb" style="text-align: right" title="Weighted Average Grant-Date Fair Value per Award, Non-vested Beginning Balance">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%">Granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zbDGwTpHaNcg" style="width: 16%; text-align: right" title="Number of Shares, Granted">681,818</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1PSx6jx1Okh" style="width: 16%; text-align: right" title="Weighted Average Grant-Date Fair Value per Award, Granted">0.33</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Vested</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zi9ZcfX2buN2" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Vested">(340,910</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zEyk8KDf3BQa" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant-Date Fair Value per Award, Vested">0.33</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Non-vested as June 30, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcPmXQBQRjqj" style="text-align: right" title="Number of Shares, Non-vested Ending Balance">340,908</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zif5VgWUgHX2" style="text-align: right" title="Weighted Average Grant-Date Fair Value per Award, Non-vested Ending Balance">0.33</td><td style="text-align: left"> </td></tr> </table> On January 1, 2026, the Company entered into restricted stock agreements with members of the Board of Directors of the Company. The Company granted <span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20260101__20260101__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zwEm2oMYvK29" title="Restricted stock awards granted">681,818 restricted stock awards with a fair market value of $<span id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_pid_uUSDPShares_c20260101__20260101__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zi4EEonNTZSa" title="Fair market value per share">0.33 per share. <span id="xdx_90B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingRights_c20260101__20260101__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zj89cisrlNRa" title="Vesting description">Such restricted stock vests as follows: 25% on the grant date in January 1, 2026, and the remaining 75% vesting 25% each on April 1, 2026, July 1, 2026 and October 1, 2026. These awards vest immediately upon a change of control as defined in the agreements. For the three months ended June 30, 2026 and 2025, the Company recognized approximately $56,000 and $1,500 for restricted stock expenses recorded in general and administrative expenses on the statement of operation. For the six months ended June 30, 2026 and 2025, the Company recognized approximately $112,000 and $155,500 for restricted stock expenses recorded in general and administrative expenses on the statement of operation. As of June 30, 2026 there was $113,000 of unrecognized compensation expense related to these awards.

11500000

28750000

P3Y

P5Y

28734635

17234635

0.27

200000

500000

0.25

750000 2000000.0 4000000.0

0.46

0.50

0.0386

0.823

P5Y2M12D

0.45

0.50

0.0175

0.866

P5Y8M12D

0.27

146000

239000

496000

158000

329000

943000000000

P2Y1M6D

<p id="xdx_894_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zYGU9LGcd622" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">A summary of option activity for employees under the plans and changes during the six months ended June 30, 2026 is presented below: SCHEDULE OF STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Averaged Exercise Price $</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Options Value $</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">Options outstanding at January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zyk2NQbQvSdf" style="width: 10%; text-align: right" title="Number of Options Outstanding, Beginning Balance">6,032,175</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z1xb6OiCXabd" style="width: 10%; text-align: right" title="Weighted Averaged Exercise Price, Beginning Balance">1.15</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_902_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zFS13mxXtcG" title="Weighted Average Remaining Contractual Life (Years), Outstanding">8.13</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zV5mTsN9deO1" style="width: 10%; text-align: right" title="Aggregate Intrinsic Options Value, Beginning Balance">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Granted during 2026(1)</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_fKDEp_zW2aYaF7Ceal" style="text-align: right" title="Number of Options, Granted">4,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_fKDEp_zYBNUNwlh1P5" style="text-align: right" title="Weighted Averaged Exercise Price, Granted">0.27</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Forfeited or expired during 2026(1)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_fKDEp_z9AQz2gEC4M3" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited or expired">(4,032,175</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98D_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_fKDEp_znVzof4SY6x4" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Averaged Exercise Price, Forfeited or expired">0.50</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Options outstanding June 30, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z5z97h5RWBy9" style="text-align: right" title="Number of Options Outstanding, Ending Balance">6,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_z7Li7cyIK9Il" style="text-align: right" title="Weighted Averaged Exercise Price, Ending Balance">1.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_90A_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zSKAsc3IgfOe" title="Weighted Average Remaining Contractual Life (Years), Outstanding">8.15</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zUx8mwvpB4l5" style="text-align: right" title="Aggregate Intrinsic Options Value, Ending Balance">200,000</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Exercisable, June 30, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zc4PgamxMiB5" style="text-align: right" title="Number of Options, Exercisable">3,000,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zNyvQWjSy4K" style="text-align: right" title="Weighted Averaged Exercise Price, Exercisable">1.73</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_900_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_zrgKdsEHZlM7" title="Weighted Average Remaining Contractual Life (Years), Exercisable">6.48</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_989_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember_ze0Nh25ZgR6a" style="text-align: right" title="Aggregate Intrinsic Options Value, Exercisable">50,000</td><td style="text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 6pt; width: 100%"><tr style="vertical-align: top; text-align: justify"> <td style="width: 15pt; text-align: right">(1)</td><td style="text-align: justify">Includes <span class="xdx_phnt_RGlzY2xvc3VyZSAtIFNDSEVEVUxFIE9GIFJFU1RSSUNURUQgU1RPQ0sgKERldGFpbHMpIChQYXJlbnRoZXRpY2FsKQA_" id="xdx_90C_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20260101__20260630__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementEmployeeMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zFq07WQmWjGa" title="Number of Options, Granted">4,000,000 stock options exchanged pursuant to the Exchange Program</td> </tr></table> <p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zqdjKVTcjUr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">A summary of option activity for non-employees under the plans and changes during the six months ended June 30, 2026 is presented below: SCHEDULE OF STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Averaged Exercise Price $</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Options Value $</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">Options outstanding at January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zf6SPakLInJg" style="width: 10%; text-align: right" title="Number of Options Outstanding, Beginning Balance">83,330</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zNUGUyJzxdO7" style="width: 10%; text-align: right" title="Weighted Averaged Exercise Price, Beginning Balance">1.59</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zeOa6Ye2eULc" title="Weighted Average Remaining Contractual Life (Years), Outstanding">2.40</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zOXdeQgaoUe" style="width: 10%; text-align: right" title="Aggregate Intrinsic Options Value, Beginning Balance">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Forfeited or expired during 2026</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zP0xR55oUgsa" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited or expired">(16,666</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zaVa9Bjqvet1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Averaged Exercise Price, Forfeited or expired">3.94</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Options outstanding June 30, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zjaN3xlLaZ88" style="text-align: right" title="Number of Options Outstanding, Ending Balance">66,664</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zBasuL63Gg82" style="text-align: right" title="Weighted Averaged Exercise Price, Ending Balance">1.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zVqjwuIMIXNd" title="Weighted Average Remaining Contractual Life (Years), Outstanding">2.45</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z5a8S4NzI9Le" style="text-align: right" title="Aggregate Intrinsic Options Value, Ending Balance">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercisable, June 30, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zEdaZIEoqIcd" style="text-align: right" title="Number of Options, Exercisable">49,994</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zGOTQLoUd67g" style="text-align: right" title="Weighted Averaged Exercise Price, Exercisable">1.02</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zjgC62RGUAEa" title="Weighted Average Remaining Contractual Life (Years), Exercisable">2.10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zubPFX0aVbv3" style="text-align: right" title="Aggregate Intrinsic Options Value, Exercisable">-</td><td style="text-align: left"> </td></tr> </table>

6032175

1.15

P8Y1M17D

4000000

0.27

4032175

0.50

6000000

1.00

P8Y1M24D

200000

3000000

1.73

P6Y5M23D

50000

4000000

<p id="xdx_891_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_hus-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zqdjKVTcjUr5" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0; text-align: justify">A summary of option activity for non-employees under the plans and changes during the six months ended June 30, 2026 is presented below: SCHEDULE OF STOCK OPTION ACTIVITY <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Options</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Averaged Exercise Price $</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Weighted Average Remaining Contractual Life (Years)</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Aggregate Intrinsic Options Value $</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%">Options outstanding at January 1, 2026</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zf6SPakLInJg" style="width: 10%; text-align: right" title="Number of Options Outstanding, Beginning Balance">83,330</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zNUGUyJzxdO7" style="width: 10%; text-align: right" title="Weighted Averaged Exercise Price, Beginning Balance">1.59</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right"><span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20250101__20251231__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zeOa6Ye2eULc" title="Weighted Average Remaining Contractual Life (Years), Outstanding">2.40</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_98F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iS_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zOXdeQgaoUe" style="width: 10%; text-align: right" title="Aggregate Intrinsic Options Value, Beginning Balance">-</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Forfeited or expired during 2026</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod_iN_di_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zP0xR55oUgsa" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Options, Forfeited or expired">(16,666</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_988_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zaVa9Bjqvet1" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Averaged Exercise Price, Forfeited or expired">3.94</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Options outstanding June 30, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zjaN3xlLaZ88" style="text-align: right" title="Number of Options Outstanding, Ending Balance">66,664</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zBasuL63Gg82" style="text-align: right" title="Weighted Averaged Exercise Price, Ending Balance">1.00</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zVqjwuIMIXNd" title="Weighted Average Remaining Contractual Life (Years), Outstanding">2.45</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_z5a8S4NzI9Le" style="text-align: right" title="Aggregate Intrinsic Options Value, Ending Balance">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Exercisable, June 30, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zEdaZIEoqIcd" style="text-align: right" title="Number of Options, Exercisable">49,994</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zGOTQLoUd67g" style="text-align: right" title="Weighted Averaged Exercise Price, Exercisable">1.02</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"><span id="xdx_906_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1_dtY_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zjgC62RGUAEa" title="Weighted Average Remaining Contractual Life (Years), Exercisable">2.10</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_984_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember__us-gaap--GranteeStatusAxis__us-gaap--ShareBasedPaymentArrangementNonemployeeMember_zubPFX0aVbv3" style="text-align: right" title="Aggregate Intrinsic Options Value, Exercisable">-</td><td style="text-align: left"> </td></tr> </table>

83330

1.59

P2Y4M24D

16666

3.94

66664

1.00

P2Y5M12D

49994

1.02

P2Y1M6D

1200

2400

1400

8000

<p id="xdx_898_eus-gaap--DisclosureOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTextBlock_hus-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zvSs19QEAlh6" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0pt 0pt 0"> SCHEDULE OF RESTRICTED STOCK <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Number of Shares</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Weighted Average Grant-Date Fair Value per Award</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Non-vested as January 1, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iS_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zuQ42Qh1Nmki" style="text-align: right" title="Number of Shares, Non-vested Beginning Balance">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iS_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zRJJvWOIu7Sb" style="text-align: right" title="Weighted Average Grant-Date Fair Value per Award, Non-vested Beginning Balance">-</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="width: 60%">Granted</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_984_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zbDGwTpHaNcg" style="width: 16%; text-align: right" title="Number of Shares, Granted">681,818</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_z1PSx6jx1Okh" style="width: 16%; text-align: right" title="Weighted Average Grant-Date Fair Value per Award, Granted">0.33</td><td style="width: 1%; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="padding-bottom: 1pt">Vested</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod_iN_di_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zi9ZcfX2buN2" style="border-bottom: Black 1pt solid; text-align: right" title="Number of Shares, Vested">(340,910</td><td style="padding-bottom: 1pt; text-align: left">)</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zEyk8KDf3BQa" style="border-bottom: Black 1pt solid; text-align: right" title="Weighted Average Grant-Date Fair Value per Award, Vested">0.33</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td>Non-vested as June 30, 2026</td><td> </td> <td style="text-align: left"> </td><td id="xdx_981_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zcPmXQBQRjqj" style="text-align: right" title="Number of Shares, Non-vested Ending Balance">340,908</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td id="xdx_987_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue_iE_c20260101__20260630__us-gaap--AwardTypeAxis__us-gaap--RestrictedStockMember_zif5VgWUgHX2" style="text-align: right" title="Weighted Average Grant-Date Fair Value per Award, Non-vested Ending Balance">0.33</td><td style="text-align: left"> </td></tr> </table>

681818

0.33

340910

0.33

340908

0.33

681818

0.33

Such restricted stock vests as follows: 25% on the grant date in January 1, 2026, and the remaining 75% vesting 25% each on April 1, 2026, July 1, 2026 and October 1, 2026

56000

1500

112000

155500

113000

NOTE 8 — INCOME TAXES The utilization of Milestone Scientific’s net operating losses may be subject to a substantial limitation due to the “change of ownership provisions” under Section 382 of the Internal Revenue Code and similar state provisions. Such limitation may result in the expiration of the net operating loss carry forwards before their utilization. Milestone Scientific has established a 100% valuation allowance for all its deferred tax assets due to uncertainty as to their future realization.

NOTE 9 — SEGMENT AND GEOGRAPHIC DATA Operating segments are reported in a manner consistent with the internal reporting provided to the chief operating decision maker. The chief operating decision maker, who is responsible for allocating resources and assessing performance of the operating segments, has been identified as the Chief Executive Officer (the “CODM”). The Company conducts its business through two reportable segments: Dental and Medical. These segments offer different products and services to different customer bases. The CODM assesses the financial performance of the segment and decides how to allocate resources based on Product sales, net, and operating income (loss). The Company provides general corporate services to its segments; however, these services are not considered when making operating decisions and assessing segment performance. These services are reported under “Corporate Services” below, and these include costs associated with executive management, investor relations, patents, trademarks, licensing agreements, new instruments developments, financing activities and public company compliance. The following tables present information about our reportable and operating segments for the three and six months ended June 30, 2026, and 2025: SCHEDULE OF REPORTABLE AND OPERATING SEGMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20260401__20260630__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zXzt4C1SHvK9" style="border-bottom: Black 1pt solid; text-align: center">Corporate</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20260401__20260630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--DentalMember_z94Dgwdf0cPc" style="border-bottom: Black 1pt solid; text-align: center">Dental</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20260401__20260630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalMember_zmNg3cXxzAFg" style="border-bottom: Black 1pt solid; text-align: center">Medical</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20260401__20260630__us-gaap--SubsegmentsAxis__custom--GrandTotalMember_zDDq4IbRLBP1" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">Three Months ended June 30, 2026</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Corporate</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Dental</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Medical</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Grand Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_zkQywj0HRQk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">Product sales, net</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">2,734,638</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">106,400</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">2,841,038</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--CostOfGoodsAndServicesSold_zBbW9U8DrCJk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Cost of products sold</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">906,033</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">24,838</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">930,871</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--GrossProfit_zHX68BrSd25d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Gross Margin</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,828,605</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">81,562</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,910,167</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LaborAndRelatedExpense_z2bgk0SqZgV" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Salaries & employee benefits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">257,658</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">396,390</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">209,249</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">863,297</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_zhsQuE93eqs" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock-based compensation expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">254,098</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">254,098</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RoyaltyExpense_zUV7IlTrpRA1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Royalty expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">145,430</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,320</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150,750</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--MarketingExpense_zqHoz0JSbvKb" style="vertical-align: bottom; background-color: White"> <td>Marketing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7,935</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">70,049</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">45,456</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">107,570</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OccupancyNet_zLhJoX5ISJUi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Rent & occupancy costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,722</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,533</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,588</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ProfessionalFees_zO6V6oKJGwDa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Consultants and professional services fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">730,328</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">34,121</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">52,810</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">817,259</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--GeneralInsuranceExpense_zyv7Nsx5dODh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41,248</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">45,554</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,284</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">127,086</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--WarehousingExpense_ztRh6fo1EqD4" style="vertical-align: bottom; background-color: White"> <td>Warehousing expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,458</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">152,147</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,776</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">175,381</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--RegulatoryExpense_zaWuSFq7ASPh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Regulatory expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">119,332</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,648</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,312</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">130,292</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--TravelAndEntertainmentExpense_z64ecCKwcZVd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Travel expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22,458</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39,628</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,225</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">87,311</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ResearchAndDevelopmentExpense_zs6QCsByD529" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Research and development expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,609</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,609</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DepreciationAndAmortization_zpxOnPWkoC61" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,589</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,589</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--SegmentReportingOtherItemAmount_zszmwLYdIsW3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Other segment items</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">71,549</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">124,222</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,129</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">201,900</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingExpenses_zntumT5WmPE5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total operating expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,527,505</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,031,331</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">412,894</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,971,730</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OperatingIncomeLoss_zFqdzf1FMPfc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,527,505</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">797,274</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(331,332</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,061,563</td><td style="text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20250401__20250630__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zOvnZqcGjyv8" style="border-bottom: Black 1pt solid; text-align: center">Corporate</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20250401__20250630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--DentalMember_z7WWqK8pBDW" style="border-bottom: Black 1pt solid; text-align: center">Dental</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20250401__20250630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalMember_z84ptztcSgX5" style="border-bottom: Black 1pt solid; text-align: center">Medical</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20250401__20250630__us-gaap--SubsegmentsAxis__custom--GrandTotalMember_zgSQ3iaYlWr3" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">Three Months ended June 30, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Corporate</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Dental</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Medical</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Grand Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_zaZMLMHljhN4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">Product sales, net</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">2,291,366</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">32,100</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">2,323,466</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--CostOfGoodsAndServicesSold_z9CEbI28jgIj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Cost of products sold</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">704,866</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">994</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">705,860</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--GrossProfit_zlrPlwpnb1q6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Gross Margin</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,586,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,106</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,617,606</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LaborAndRelatedExpense_zRyzCk6iUTY7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Salaries & employee benefits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">206,777</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">440,463</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">192,733</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">839,973</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_zhI1iocLJl23" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock-based compensation expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">159,678</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">159,678</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RoyaltyExpense_zwsT0WXOY6Ml" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Royalty expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">118,174</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,605</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">119,779</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--MarketingExpense_zKRPeAQI27Z4" style="vertical-align: bottom; background-color: White"> <td>Marketing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,156</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">48,047</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,907</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">78,110</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OccupancyNet_zrnqkLSEYH4e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Rent & occupancy costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21,703</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,852</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,657</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">44,212</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ProfessionalFees_zrl0QdgtlVBf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Consultants and professional services fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">698,388</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">83,134</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">119,069</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">900,591</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--GeneralInsuranceExpense_z5OysCgib1p5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,503</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">45,225</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,078</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">125,806</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--WarehousingExpense_z81SdEVVajn9" style="vertical-align: bottom; background-color: White"> <td>Warehousing expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,033</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">106,685</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,188</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">128,906</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--RegulatoryExpense_zCEPcj9vhxR4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Regulatory expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">263,931</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">66,144</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,087</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">333,162</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--TravelAndEntertainmentExpense_zDclRNVl52q6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Travel expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,005</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,870</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35,330</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">73,205</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_zLpXMZsKCb5a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Research and development expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">47,089</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,700</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">51,789</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DepreciationAndAmortization_zSNDzRu9zjld" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,496</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,496</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--SegmentReportingOtherItemAmount_zaVJFMuMInd6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Other segment items</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">79,433</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">136,193</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">11,904</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">227,530</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingExpenses_z4a84ojqvkxg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total operating expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,517,103</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,130,876</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">454,258</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,102,237</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingIncomeLoss_zraFtHZZcYLf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,517,103</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">455,624</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(423,152</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,484,631</td><td style="text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20260101__20260630__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zFNWlEZo02bi" style="border-bottom: Black 1pt solid; text-align: center">Corporate</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20260101__20260630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--DentalMember_zaXP3KRfRRH2" style="border-bottom: Black 1pt solid; text-align: center">Dental</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20260101__20260630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalMember_z7oCfAlFTR32" style="border-bottom: Black 1pt solid; text-align: center">Medical</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20260101__20260630__us-gaap--SubsegmentsAxis__custom--GrandTotalMember_z4IQvCkvXE64" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">Six Months ended June 30, 2026</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Corporate</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Dental</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Medical</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Grand Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_zeWvhDfYvbLj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">Product sales, net</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">4,789,071</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">214,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">5,003,071</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--CostOfGoodsAndServicesSold_zWuBhghgxJJ6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Cost of products sold</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,490,614</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">38,266</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,528,880</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--GrossProfit_zeCjI2BxkCIa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Gross Margin</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,298,457</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">175,734</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,474,191</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LaborAndRelatedExpense_zRe5oMD8qkpc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Salaries & employee benefits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">434,908</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">815,841</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">437,554</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,688,303</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_zCAbqT8RTepd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock-based compensation expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">566,261</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">566,261</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RoyaltyExpense_zO3WCAk0qej8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Royalty expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">235,668</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,700</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">246,368</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--MarketingExpense_zn4vQtvoRqb" style="vertical-align: bottom; background-color: White"> <td>Marketing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23,455</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">106,416</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">51,424</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">181,295</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OccupancyNet_zxoRzZr6Jno4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Rent & occupancy costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">36,455</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,599</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,999</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">78,053</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ProfessionalFees_zGVwndar6Ezb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Consultants and professional services fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">991,573</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">62,838</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">154,688</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,209,099</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--GeneralInsuranceExpense_zYUa32gaWqjk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">83,074</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">91,647</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">80,904</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">255,625</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--WarehousingExpense_z9L0Tv5oxVs6" style="vertical-align: bottom; background-color: White"> <td>Warehousing expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,741</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">283,243</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,177</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">305,161</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--RegulatoryExpense_zc1MxoH7iDGj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Regulatory expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">208,138</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,133</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,625</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">224,896</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--TravelAndEntertainmentExpense_z0iHQyn1YYxe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Travel expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,848</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">64,957</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">36,036</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">147,841</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ResearchAndDevelopmentExpense_zbAmK0j7zsLk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Research and development expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,609</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,609</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DepreciationAndAmortization_zmR5qpK37lXf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39,043</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39,043</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--SegmentReportingOtherItemAmount_zEBdTe1pokZa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Other segment items</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">144,884</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">260,397</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,001</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">415,282</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingExpenses_z9POscl9jNz2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total operating expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,578,380</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,965,348</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">820,108</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,363,836</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingIncomeLoss_zEaE9V4c5Qoc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,578,380</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,333,109</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(644,374</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,889,645</td><td style="text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20250101__20250630__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zCiTyGTUCFoi" style="border-bottom: Black 1pt solid; text-align: center">Corporate</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20250101__20250630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--DentalMember_zGfZ5rpvFGy3" style="border-bottom: Black 1pt solid; text-align: center">Dental</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20250101__20250630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalMember_zZOrve4tLtQl" style="border-bottom: Black 1pt solid; text-align: center">Medical</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20250101__20250630__us-gaap--SubsegmentsAxis__custom--GrandTotalMember_zf1yrHNqhAba" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">Six Months ended June 30, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Corporate</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Dental</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Medical</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Grand Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_zX7rj6n3kxd8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">Product sales, net</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">4,472,536</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">83,350</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">4,555,886</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--CostOfGoodsAndServicesSold_zKoCo9QIHqM2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Cost of products sold</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,289,761</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,084</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,290,845</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--GrossProfit_zFLE1h9lhwza" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Gross Margin</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,182,775</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">82,266</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,265,041</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LaborAndRelatedExpense_zCJm2YimDyXl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Salaries & employee benefits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">323,885</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">881,961</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">398,847</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,604,693</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_zyjbooL6dlZ8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock-based compensation expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">490,466</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">490,466</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RoyaltyExpense_za3NKWPjZpYl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Royalty expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">228,102</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,168</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">232,270</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--MarketingExpense_zYptWQeGatGf" style="vertical-align: bottom; background-color: White"> <td>Marketing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,417</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">131,676</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">44,227</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">190,320</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OccupancyNet_zljinJeGNDod" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Rent & occupancy costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">34,411</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26,373</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,483</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">77,267</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ProfessionalFees_zuyL70pnecP7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Consultants and professional services fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,783,082</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">140,795</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">261,359</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,185,236</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--GeneralInsuranceExpense_zPjfGGOaVHY5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">83,375</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">94,222</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">82,514</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">260,111</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--WarehousingExpense_zqPT4ehXOCB2" style="vertical-align: bottom; background-color: White"> <td>Warehousing expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,238</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">219,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,961</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">251,199</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--RegulatoryExpense_zA2Tali9j1Ej" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Regulatory expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">328,821</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">82,994</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,399</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">417,214</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--TravelAndEntertainmentExpense_z488GSuiZjE9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Travel expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,479</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">57,538</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">65,292</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">139,309</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--ResearchAndDevelopmentExpense_zcOIWlBFu48i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Research and development expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">411,896</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,013</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">420,909</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DepreciationAndAmortization_zU4w4jPfTuU3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">38,936</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">38,936</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--SegmentReportingOtherItemAmount_z7JHzchIUBnl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Other segment items</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">152,951</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">273,239</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">13,405</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">439,595</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingExpenses_zjfGIKdtdgT8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total operating expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,273,061</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,547,796</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">926,668</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,747,525</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingIncomeLoss_zouaAE23fZn7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,273,061</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">634,979</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(844,402</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,482,484</td><td style="text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="17" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Dental</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Medical</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Corporate</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left; padding-bottom: 1pt">Total Assets</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--Assets_iI_c20260630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--DentalSegmentMember_zmFW2vzIiS8f" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Total assets">5,271,616</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--Assets_iI_c20260630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalSegmentMember_zj00lRf0hXgj" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Total assets">381,309</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--Assets_iI_c20260630__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_z6i8GEsU4t82" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Total assets">2,694,873</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--Assets_iI_c20260630_zuUqXMJlBI08" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Total assets">8,347,798</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--Assets_iI_c20260630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--DentalSegmentMember_zA0h2f8ybGl1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">5,271,616</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--Assets_iI_c20260630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalSegmentMember_z5CaBZ0Ii5v1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">381,309</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--Assets_iI_c20260630__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zmU5nHj4EBIe" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">2,694,873</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--Assets_iI_c20260630_zUYK8xuukX3a" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">8,347,798</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="17" style="text-align: center">December 31, 2025</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Dental</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Medical</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Corporate</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left; padding-bottom: 1pt">Total Assets</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--Assets_iI_c20251231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--DentalSegmentMember_zsfMqb40nLta" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Total assets">5,861,323</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--Assets_iI_c20251231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalSegmentMember_za8z8XPVjIYf" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Total assets">394,267</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--Assets_iI_c20251231__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zhnODa81q5rf" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Total assets">1,550,839</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--Assets_iI_c20251231_zKvhJhl2ye9f" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Total assets">7,806,429</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--Assets_iI_c20251231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--DentalSegmentMember_z34dcLyNgPO2" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">5,861,323</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--Assets_iI_c20251231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalSegmentMember_ziStPxgItT9c" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">394,267</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--Assets_iI_c20251231__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zTjR12rSJe7j" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">1,550,839</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--Assets_iI_c20251231_zKEqJjHoa8qg" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">7,806,429</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

The following tables present information about our reportable and operating segments for the three and six months ended June 30, 2026, and 2025: SCHEDULE OF REPORTABLE AND OPERATING SEGMENTS <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_492_20260401__20260630__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zXzt4C1SHvK9" style="border-bottom: Black 1pt solid; text-align: center">Corporate</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_491_20260401__20260630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--DentalMember_z94Dgwdf0cPc" style="border-bottom: Black 1pt solid; text-align: center">Dental</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_494_20260401__20260630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalMember_zmNg3cXxzAFg" style="border-bottom: Black 1pt solid; text-align: center">Medical</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20260401__20260630__us-gaap--SubsegmentsAxis__custom--GrandTotalMember_zDDq4IbRLBP1" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">Three Months ended June 30, 2026</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Corporate</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Dental</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Medical</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Grand Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_405_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_zkQywj0HRQk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">Product sales, net</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">2,734,638</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">106,400</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">2,841,038</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--CostOfGoodsAndServicesSold_zBbW9U8DrCJk" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Cost of products sold</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">906,033</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">24,838</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">930,871</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--GrossProfit_zHX68BrSd25d" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Gross Margin</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,828,605</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">81,562</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,910,167</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LaborAndRelatedExpense_z2bgk0SqZgV" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Salaries & employee benefits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">257,658</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">396,390</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">209,249</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">863,297</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_zhsQuE93eqs" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock-based compensation expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">254,098</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">254,098</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RoyaltyExpense_zUV7IlTrpRA1" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Royalty expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">145,430</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,320</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">150,750</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--MarketingExpense_zqHoz0JSbvKb" style="vertical-align: bottom; background-color: White"> <td>Marketing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(7,935</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">70,049</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">45,456</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">107,570</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OccupancyNet_zLhJoX5ISJUi" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Rent & occupancy costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,722</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,533</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,333</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">30,588</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ProfessionalFees_zO6V6oKJGwDa" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Consultants and professional services fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">730,328</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">34,121</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">52,810</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">817,259</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--GeneralInsuranceExpense_zyv7Nsx5dODh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">41,248</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">45,554</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,284</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">127,086</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--WarehousingExpense_ztRh6fo1EqD4" style="vertical-align: bottom; background-color: White"> <td>Warehousing expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,458</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">152,147</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">20,776</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">175,381</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--RegulatoryExpense_zaWuSFq7ASPh" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Regulatory expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">119,332</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,648</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,312</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">130,292</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--TravelAndEntertainmentExpense_z64ecCKwcZVd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Travel expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">22,458</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39,628</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,225</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">87,311</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ResearchAndDevelopmentExpense_zs6QCsByD529" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Research and development expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,609</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,609</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--DepreciationAndAmortization_zpxOnPWkoC61" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,589</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,589</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--SegmentReportingOtherItemAmount_zszmwLYdIsW3" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Other segment items</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">71,549</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">124,222</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">6,129</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">201,900</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--OperatingExpenses_zntumT5WmPE5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total operating expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,527,505</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,031,331</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">412,894</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,971,730</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--OperatingIncomeLoss_zFqdzf1FMPfc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,527,505</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">797,274</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(331,332</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,061,563</td><td style="text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20250401__20250630__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zOvnZqcGjyv8" style="border-bottom: Black 1pt solid; text-align: center">Corporate</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20250401__20250630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--DentalMember_z7WWqK8pBDW" style="border-bottom: Black 1pt solid; text-align: center">Dental</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20250401__20250630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalMember_z84ptztcSgX5" style="border-bottom: Black 1pt solid; text-align: center">Medical</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49B_20250401__20250630__us-gaap--SubsegmentsAxis__custom--GrandTotalMember_zgSQ3iaYlWr3" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">Three Months ended June 30, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Corporate</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Dental</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Medical</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Grand Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_zaZMLMHljhN4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">Product sales, net</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">2,291,366</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">32,100</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">2,323,466</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--CostOfGoodsAndServicesSold_z9CEbI28jgIj" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Cost of products sold</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">704,866</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">994</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">705,860</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--GrossProfit_zlrPlwpnb1q6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Gross Margin</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,586,500</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">31,106</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,617,606</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LaborAndRelatedExpense_zRyzCk6iUTY7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Salaries & employee benefits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">206,777</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">440,463</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">192,733</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">839,973</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_zhI1iocLJl23" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock-based compensation expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">159,678</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">159,678</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RoyaltyExpense_zwsT0WXOY6Ml" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Royalty expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">118,174</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,605</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">119,779</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--MarketingExpense_zKRPeAQI27Z4" style="vertical-align: bottom; background-color: White"> <td>Marketing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,156</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">48,047</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,907</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">78,110</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OccupancyNet_zrnqkLSEYH4e" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Rent & occupancy costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">21,703</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">13,852</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">8,657</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">44,212</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ProfessionalFees_zrl0QdgtlVBf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Consultants and professional services fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">698,388</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">83,134</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">119,069</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">900,591</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--GeneralInsuranceExpense_z5OysCgib1p5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,503</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">45,225</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">40,078</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">125,806</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--WarehousingExpense_z81SdEVVajn9" style="vertical-align: bottom; background-color: White"> <td>Warehousing expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,033</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">106,685</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">17,188</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">128,906</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--RegulatoryExpense_zCEPcj9vhxR4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Regulatory expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">263,931</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">66,144</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,087</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">333,162</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--TravelAndEntertainmentExpense_zDclRNVl52q6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Travel expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,005</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,870</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">35,330</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">73,205</td><td style="text-align: left"> </td></tr> <tr id="xdx_406_eus-gaap--ResearchAndDevelopmentExpense_zLpXMZsKCb5a" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Research and development expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">47,089</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,700</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">51,789</td><td style="text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--DepreciationAndAmortization_zSNDzRu9zjld" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,496</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">19,496</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--SegmentReportingOtherItemAmount_zaVJFMuMInd6" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Other segment items</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">79,433</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">136,193</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">11,904</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">227,530</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingExpenses_z4a84ojqvkxg" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total operating expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,517,103</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,130,876</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">454,258</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,102,237</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingIncomeLoss_zraFtHZZcYLf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Operating income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,517,103</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">455,624</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(423,152</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,484,631</td><td style="text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49E_20260101__20260630__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zFNWlEZo02bi" style="border-bottom: Black 1pt solid; text-align: center">Corporate</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_490_20260101__20260630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--DentalMember_zaXP3KRfRRH2" style="border-bottom: Black 1pt solid; text-align: center">Dental</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20260101__20260630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalMember_z7oCfAlFTR32" style="border-bottom: Black 1pt solid; text-align: center">Medical</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_496_20260101__20260630__us-gaap--SubsegmentsAxis__custom--GrandTotalMember_z4IQvCkvXE64" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">Six Months ended June 30, 2026</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Corporate</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Dental</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Medical</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Grand Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_zeWvhDfYvbLj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">Product sales, net</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">4,789,071</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">214,000</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">5,003,071</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--CostOfGoodsAndServicesSold_zWuBhghgxJJ6" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Cost of products sold</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,490,614</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">38,266</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,528,880</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--GrossProfit_zeCjI2BxkCIa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Gross Margin</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,298,457</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">175,734</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,474,191</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LaborAndRelatedExpense_zRe5oMD8qkpc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Salaries & employee benefits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">434,908</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">815,841</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">437,554</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,688,303</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_zCAbqT8RTepd" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock-based compensation expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">566,261</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">566,261</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RoyaltyExpense_zO3WCAk0qej8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Royalty expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">235,668</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">10,700</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">246,368</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--MarketingExpense_zn4vQtvoRqb" style="vertical-align: bottom; background-color: White"> <td>Marketing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">23,455</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">106,416</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">51,424</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">181,295</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OccupancyNet_zxoRzZr6Jno4" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Rent & occupancy costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">36,455</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,599</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">15,999</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">78,053</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ProfessionalFees_zGVwndar6Ezb" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Consultants and professional services fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">991,573</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">62,838</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">154,688</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,209,099</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--GeneralInsuranceExpense_zYUa32gaWqjk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">83,074</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">91,647</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">80,904</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">255,625</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--WarehousingExpense_z9L0Tv5oxVs6" style="vertical-align: bottom; background-color: White"> <td>Warehousing expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,741</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">283,243</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">18,177</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">305,161</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--RegulatoryExpense_zc1MxoH7iDGj" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Regulatory expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">208,138</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">12,133</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,625</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">224,896</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--TravelAndEntertainmentExpense_z0iHQyn1YYxe" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Travel expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">46,848</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">64,957</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">36,036</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">147,841</td><td style="text-align: left"> </td></tr> <tr id="xdx_401_eus-gaap--ResearchAndDevelopmentExpense_zbAmK0j7zsLk" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Research and development expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,609</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,609</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DepreciationAndAmortization_zmR5qpK37lXf" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39,043</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">39,043</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--SegmentReportingOtherItemAmount_zEBdTe1pokZa" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Other segment items</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">144,884</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">260,397</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">10,001</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">415,282</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingExpenses_z9POscl9jNz2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total operating expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,578,380</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,965,348</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">820,108</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,363,836</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingIncomeLoss_zEaE9V4c5Qoc" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(2,578,380</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,333,109</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(644,374</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(1,889,645</td><td style="text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20250101__20250630__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zCiTyGTUCFoi" style="border-bottom: Black 1pt solid; text-align: center">Corporate</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_498_20250101__20250630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--DentalMember_zGfZ5rpvFGy3" style="border-bottom: Black 1pt solid; text-align: center">Dental</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_495_20250101__20250630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalMember_zZOrve4tLtQl" style="border-bottom: Black 1pt solid; text-align: center">Medical</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49A_20250101__20250630__us-gaap--SubsegmentsAxis__custom--GrandTotalMember_zf1yrHNqhAba" style="border-bottom: Black 1pt solid; text-align: center">Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="14" style="border-bottom: Black 1pt solid; text-align: center">Six Months ended June 30, 2025</td><td style="padding-bottom: 1pt"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Corporate</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Dental</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Medical</td><td style="padding-bottom: 1pt"> </td><td style="padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; text-align: center">Grand Total</td><td style="padding-bottom: 1pt"> </td></tr> <tr id="xdx_402_eus-gaap--RevenueFromContractWithCustomerIncludingAssessedTax_zX7rj6n3kxd8" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left">Product sales, net</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">-</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">4,472,536</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">83,350</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left"> </td><td style="width: 10%; text-align: right">4,555,886</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--CostOfGoodsAndServicesSold_zKoCo9QIHqM2" style="vertical-align: bottom; background-color: White"> <td style="text-align: left; padding-bottom: 1pt">Cost of products sold</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">-</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,289,761</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,084</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">1,290,845</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40C_eus-gaap--GrossProfit_zFLE1h9lhwza" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Gross Margin</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,182,775</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">82,266</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,265,041</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--LaborAndRelatedExpense_zCJm2YimDyXl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Salaries & employee benefits</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">323,885</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">881,961</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">398,847</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,604,693</td><td style="text-align: left"> </td></tr> <tr id="xdx_40A_eus-gaap--AllocatedShareBasedCompensationExpense_zyjbooL6dlZ8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Stock-based compensation expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">490,466</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">490,466</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--RoyaltyExpense_za3NKWPjZpYl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Royalty expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">228,102</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">4,168</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">232,270</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--MarketingExpense_zYptWQeGatGf" style="vertical-align: bottom; background-color: White"> <td>Marketing</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">14,417</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">131,676</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">44,227</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">190,320</td><td style="text-align: left"> </td></tr> <tr id="xdx_400_eus-gaap--OccupancyNet_zljinJeGNDod" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Rent & occupancy costs</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">34,411</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">26,373</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,483</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">77,267</td><td style="text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--ProfessionalFees_zuyL70pnecP7" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Consultants and professional services fees</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">1,783,082</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">140,795</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">261,359</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,185,236</td><td style="text-align: left"> </td></tr> <tr id="xdx_403_eus-gaap--GeneralInsuranceExpense_zPjfGGOaVHY5" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Insurance</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">83,375</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">94,222</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">82,514</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">260,111</td><td style="text-align: left"> </td></tr> <tr id="xdx_402_ecustom--WarehousingExpense_zqPT4ehXOCB2" style="vertical-align: bottom; background-color: White"> <td>Warehousing expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,238</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">219,000</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">25,961</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">251,199</td><td style="text-align: left"> </td></tr> <tr id="xdx_409_ecustom--RegulatoryExpense_zA2Tali9j1Ej" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td>Regulatory expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">328,821</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">82,994</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">5,399</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">417,214</td><td style="text-align: left"> </td></tr> <tr id="xdx_408_eus-gaap--TravelAndEntertainmentExpense_z488GSuiZjE9" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Travel expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">16,479</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">57,538</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">65,292</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">139,309</td><td style="text-align: left"> </td></tr> <tr id="xdx_404_eus-gaap--ResearchAndDevelopmentExpense_zcOIWlBFu48i" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Research and development expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">411,896</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9,013</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">420,909</td><td style="text-align: left"> </td></tr> <tr id="xdx_40B_eus-gaap--DepreciationAndAmortization_zU4w4jPfTuU3" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Depreciation and amortization expense</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">38,936</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">-</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">38,936</td><td style="text-align: left"> </td></tr> <tr id="xdx_405_eus-gaap--SegmentReportingOtherItemAmount_z7JHzchIUBnl" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left; padding-bottom: 1pt">Other segment items</td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">152,951</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">273,239</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">13,405</td><td style="padding-bottom: 1pt; text-align: left"> </td><td style="padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; text-align: left"> </td><td style="border-bottom: Black 1pt solid; text-align: right">439,595</td><td style="padding-bottom: 1pt; text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingExpenses_zjfGIKdtdgT8" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Total operating expenses</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,273,061</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">2,547,796</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">926,668</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,747,525</td><td style="text-align: left"> </td></tr> <tr id="xdx_40D_eus-gaap--OperatingIncomeLoss_zouaAE23fZn7" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating income (loss)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,273,061</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">634,979</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(844,402</td><td style="text-align: left">)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">(3,482,484</td><td style="text-align: left">)</td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="17" style="border-bottom: Black 1pt solid; text-align: center">June 30, 2026</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Dental</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Medical</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Corporate</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left; padding-bottom: 1pt">Total Assets</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--Assets_iI_c20260630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--DentalSegmentMember_zmFW2vzIiS8f" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Total assets">5,271,616</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98F_eus-gaap--Assets_iI_c20260630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalSegmentMember_zj00lRf0hXgj" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Total assets">381,309</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--Assets_iI_c20260630__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_z6i8GEsU4t82" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Total assets">2,694,873</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_982_eus-gaap--Assets_iI_c20260630_zuUqXMJlBI08" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Total assets">8,347,798</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_980_eus-gaap--Assets_iI_c20260630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--DentalSegmentMember_zA0h2f8ybGl1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">5,271,616</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--Assets_iI_c20260630__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalSegmentMember_z5CaBZ0Ii5v1" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">381,309</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98E_eus-gaap--Assets_iI_c20260630__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zmU5nHj4EBIe" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">2,694,873</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--Assets_iI_c20260630_zUYK8xuukX3a" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">8,347,798</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table> <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="vertical-align: bottom"> <td colspan="17" style="text-align: center">December 31, 2025</td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Dental</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Medical</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Corporate</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">Total</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 44%; text-align: left; padding-bottom: 1pt">Total Assets</td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_981_eus-gaap--Assets_iI_c20251231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--DentalSegmentMember_zsfMqb40nLta" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Total assets">5,861,323</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_984_eus-gaap--Assets_iI_c20251231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalSegmentMember_za8z8XPVjIYf" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Total assets">394,267</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_98B_eus-gaap--Assets_iI_c20251231__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zhnODa81q5rf" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Total assets">1,550,839</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td><td style="width: 2%; padding-bottom: 1pt"> </td> <td style="border-bottom: Black 1pt solid; width: 1%; text-align: left">$</td><td id="xdx_985_eus-gaap--Assets_iI_c20251231_zKvhJhl2ye9f" style="border-bottom: Black 1pt solid; width: 10%; text-align: right" title="Total assets">7,806,429</td><td style="width: 1%; padding-bottom: 1pt; text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="padding-bottom: 2.5pt"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_98A_eus-gaap--Assets_iI_c20251231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--DentalSegmentMember_z34dcLyNgPO2" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">5,861,323</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_984_eus-gaap--Assets_iI_c20251231__srt--ConsolidationItemsAxis__us-gaap--OperatingSegmentsMember__us-gaap--StatementBusinessSegmentsAxis__custom--MedicalSegmentMember_ziStPxgItT9c" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">394,267</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--Assets_iI_c20251231__srt--ConsolidationItemsAxis__us-gaap--CorporateNonSegmentMember_zTjR12rSJe7j" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">1,550,839</td><td style="padding-bottom: 2.5pt; text-align: left"> </td><td style="padding-bottom: 2.5pt"> </td> <td style="border-bottom: Black 2.5pt double; text-align: left"> </td><td id="xdx_989_eus-gaap--Assets_iI_c20251231_zKEqJjHoa8qg" style="border-bottom: Black 2.5pt double; text-align: right" title="Total assets">7,806,429</td><td style="padding-bottom: 2.5pt; text-align: left"> </td></tr> </table>

2734638

106400

2841038

906033

24838

930871

1828605

81562

1910167

257658

396390

209249

863297

254098

145430

5320

150750

-7935

70049

45456

107570

16722

8533

5333

30588

730328

34121

52810

817259

41248

45554

40284

127086

2458 152147 20776 175381 119332 8648 2312 130292

22458

39628

25225

87311

6609

19589

71549

124222

6129

201900

1527505

1031331

412894

2971730

-1527505

797274

-331332

-1061563

2291366

32100

2323466

704866

994

705860

1586500

31106

1617606

206777

440463

192733

839973

159678

118174

1605

119779

10156

48047

19907

78110

21703

13852

8657

44212

698388

83134

119069

900591

40503

45225

40078

125806

5033 106685 17188 128906 263931 66144 3087 333162

12005

25870

35330

73205

47089

4700

51789

19496

79433

136193

11904

227530

1517103

1130876

454258

3102237

-1517103

455624

-423152

-1484631

4789071

214000

5003071

1490614

38266

1528880

3298457

175734

3474191

434908

815841

437554

1688303

566261

235668

10700

246368

23455

106416

51424

181295

36455

25599

15999

78053

991573

62838

154688

1209099

83074

91647

80904

255625

3741 283243 18177 305161 208138 12133 4625 224896

46848

64957

36036

147841

6609

39043

144884

260397

10001

415282

2578380

1965348

820108

5363836

-2578380

1333109

-644374

-1889645

4472536

83350

4555886

1289761

1084

1290845

3182775

82266

3265041

323885

881961

398847

1604693

490466

228102

4168

232270

14417

131676

44227

190320

34411

26373

16483

77267

1783082

140795

261359

2185236

83375

94222

82514

260111

6238 219000 25961 251199 328821 82994 5399 417214

16479

57538

65292

139309

411896

9013

420909

38936

152951

273239

13405

439595

3273061

2547796

926668

6747525

-3273061

634979

-844402

-3482484

5271616

381309

2694873

8347798

5271616

381309

2694873

8347798

5861323

394267

1550839

7806429

5861323

394267

1550839

7806429

NOTE 10 – CONCENTRATIONS Milestone Scientific has informal arrangements with third-party U.S. manufacturers of the STA devices and epidural instruments pursuant to which they manufacture these products under specific purchase orders that contain advance payments for long lead items for production. Advances on contracts have been classified as current at June 30, 2026 and December 31, 2025. The termination of the manufacturing relationship with any of these manufacturers could have a material adverse effect on Milestone Scientific’s ability to produce and sell its products. Although alternate sources of supply exist, and new manufacturing relationships could be established, Milestone Scientific would need to recover its existing tools or have new tools produced. Establishment of new manufacturing relationships could involve significant expense and delay. Any curtailment or interruption of the supply, because of the termination of such a relationship, would have a material adverse effect on Milestone Scientific’s financial condition, business, and results of operations. On January 3, 2023, the Company launched an E-Commerce platform selling and shipping STA instruments and handpieces directly to dental offices and dental groups within the U.S. For the three months ended June 30, 2026, E-Commerce accounted for <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20260401__20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ECommerceMember_zyUtsFsbxqG5" title="Concentration risk, percentage">41% of net product sales, and <span id="xdx_904_ecustom--NumberOfDistributors_do_uInteger_c20260401__20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--DistributorOneMember_zdrybpo7XuBh" title="Concentration risk, percentage">no international distributors accounted for over <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20260401__20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--DistributorOneMember_zfvo1d7iDBLi" title="Concentration risk, percentage">10% of net product sales. For the three months ended June 30, 2025, E-commerce accounted for <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250401__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ECommerceMember_z7b9abio8sec" title="Concentration risk, percentage">53% of net product sales, and <span id="xdx_90E_ecustom--NumberOfDistributors_dc_uInteger_c20250401__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--DistributorOneMember_zbjWj5gbfG71" title="Number of distributors">one international distributor accounted for <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250401__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--DistributorOneMember_zN4ybnPENkYe" title="Concentration risk, percentage">10% of net product sales. For the six months ended June 30, 2026, E-Commerce accounted for <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20260101__20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ECommerceMember_z5aDk1TwmUz4" title="Concentration risk, percentage">45% of net product sales, and <span id="xdx_901_ecustom--NumberOfDistributors_do_uInteger_c20260101__20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--DistributorOneMember_z2nUEIKNn7wa" title="Concentration risk, percentage">no international distributors accounted for over <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20260101__20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--DistributorOneMember_zqh83YfxDjPd" title="Concentration risk, percentage">10% of net product sales. For the six months ended June 30, 2025, E-commerce accounted for <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--ECommerceMember_zIhHDK1IKsri" title="Concentration risk, percentage">50% of net product sales, and no international distributor accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20250630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--DistributorOneMember_zsfscxfpbfT" title="Concentration risk, percentage">10% of net product sales. The Company had <span id="xdx_90E_ecustom--NumberOfDistributors_dc_uInteger_c20260101__20260630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_z8LRdfEDnUz8" title="Number of distributors">three distributors that accounted for <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20260101__20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--DistributorOneMember_zJwEIuP7Vtzc" title="Concentration risk, percentage">20%, <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20260101__20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__srt--MajorCustomersAxis__custom--DistributorTwoMember_zCp9rOOC4Ewi" title="Concentration risk, percentage">13%, <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20260101__20260630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--DistributorThreeMember_zHaGhTJ0DQnk" title="Concentration risk, percentage">11% of accounts receivable, respectively, as of June 30, 2026. The Company had <span id="xdx_907_ecustom--NumberOfDistributors_dc_uInteger_c20250101__20251231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember_zc1nZjy31NQi" title="Number of distributors">three distributors that accounted for <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20251231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--DistributorOneMember_z55jL72Lptcl" title="Concentration risk, percentage">32%, <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20251231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--DistributorTwoMember_zikDuhesKFu2" title="Concentration risk, percentage">21% and <span id="xdx_90B_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20251231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__srt--MajorCustomersAxis__custom--DistributorThreeMember_zJ2DEpOKEBgf" title="Concentration risk, percentage">11% of accounts receivable, respectively as of December 31, 2025. As of June 30, 2026, the Company had <span id="xdx_90E_ecustom--NumberOfSuppliers_dc_uInteger_c20260101__20260630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember_zCFJ1vJ7oIpd" title="Number of suppliers">three suppliers that accounted for <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20260101__20260630__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__srt--MajorCustomersAxis__custom--SupplierOneMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zmoSy9QPDuX3" title="Concentration risk, percentage">22%, <span id="xdx_900_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20260101__20260630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__srt--MajorCustomersAxis__custom--SupplierTwoMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z4iL1wkt2UW7" title="Concentration risk, percentage">20%, and <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20260101__20260630__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__srt--MajorCustomersAxis__custom--SupplierThreeMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_z1ki3mVyclfg" title="Concentration risk, percentage">12% respectively, of accounts payable and accounts payable, related party. The Company had <span id="xdx_90F_ecustom--NumberOfSuppliers_dc_uInteger_c20250101__20251231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember_z6w9XlR1tv9" title="Number of suppliers">three suppliers that accounted for <span id="xdx_90F_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20251231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__srt--MajorCustomersAxis__custom--SupplierOneMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zxmLRBm5BcBi" title="Concentration risk, percentage">38%, <span id="xdx_903_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20251231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__srt--MajorCustomersAxis__custom--SupplierTwoMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zy2VTDP7I4Ef" title="Concentration risk, percentage">22%, and <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20250101__20251231__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--SupplierConcentrationRiskMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__srt--MajorCustomersAxis__custom--SupplierThreeMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__us-gaap--RelatedPartyMember_zA42zVoks1ae" title="Concentration risk, percentage">10%, respectively of accounts payable and accounts payable, related to the party as of December 31, 2025.

0.41

0.10

0.53

0.10

0.45

0.10

0.50

0.10

0.20

0.13

0.11

0.32

0.21

0.11

0.22

0.20

0.12

0.38

0.22

0.10

NOTE 11 — RELATED PARTY TRANSACTIONS United Systems In June 2021, the Company entered into a ten-year supply agreement with United Systems, the principal supplier of its handpieces. United Systems is considered a related party because its controlling shareholder, Tom Cheng, is also a stockholder of the Company. Under the agreement, the Company procures products pursuant to individual purchase orders and has no minimum purchase commitments. Purchases from this supplier were approximately $<span id="xdx_900_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20260401__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnitedSystemsMember_zIbHaX3jNC4e" title="Purchases from supplier">222,000 and $<span id="xdx_90D_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnitedSystemsMember_zocncHJ3wrBg" title="Purchases from supplier">471,000 for the three and six months ended June 30, 2026. Purchases from this supplier were approximately $<span id="xdx_909_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20250401__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnitedSystemsMember_zmg4vIqbqap7" title="Purchases from supplier">285,000 and $<span id="xdx_905_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20250101__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnitedSystemsMember_zHK2aDuuSIGb" title="Purchases from supplier">772,000 for the three and six months ended June 30, 2025. As of June 30, 2026, and December 31, 2025, Milestone Scientific owed this supplier approximately $<span id="xdx_907_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iI_c20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnitedSystemsMember_z1oWucP4fMJb" title="Amounts owed">667,000 and $<span id="xdx_905_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrentAndNoncurrent_iI_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UnitedSystemsMember_zMFlDLel6WBh" title="Amounts owed">1,100,000, respectively, which is included in accounts payable and accrued expenses related party on the unaudited condensed consolidated balance sheets. Director of Clinical Affairs The Company pays royalty fees to its Director of Clinical Affairs pursuant to a Technology Sale Agreement, as amended, relating to Company products embodying technology covered by patents purchased by the Company from the Director of Clinical Affairs, including U.S. Patent No. 7,625,354, relating to the Company’s computer-controlled local anesthetic delivery system and associated handpiece, and U.S. Patent No. 7,618,409, relating to methods of administering an anesthetic using the system and handpiece. Royalty fee attributable to the Director of Clinical Affairs was approximately $151,000 and $246,000 for the three and six months ended June 30, 2026, respectively, compared with approximately $119,000 and $232,000 for the three and six months ended June 30, 2025, respectively. In addition, consulting expense attributable to the Director of Clinical Affairs was approximately $<span id="xdx_90C_ecustom--PaymentsForConsultingServices_c20260401__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorClinicalAffairMember_zZKEzenaYxwe" title="Consulting fee payable">25,000 and $<span id="xdx_90C_ecustom--PaymentsForConsultingServices_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorClinicalAffairMember_zOGkCPmSI2We" title="Consulting fee payable">50,000 for the three and six months ended June 30, 2026, respectively, compared with approximately $<span id="xdx_90A_ecustom--PaymentsForConsultingServices_c20250401__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorClinicalAffairMember_zZz73sKr5rw1" title="Consulting fee payable">39,000 and $<span id="xdx_90B_ecustom--PaymentsForConsultingServices_c20250101__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorClinicalAffairMember_zO8aND4g4v56" title="Consulting fee payable">78,000 for the three and six months ended June 30, 2025, respectively. Under such Technology Sale Agreement, as amended, the Director of Clinical Affairs is also entitled to receive stock options upon the issuance of patents for inventions made by the Director of Clinical Affairs and purchased by the Company. Any options granted upon the achievement of such patent-related milestones are measured and recognized as stock-based compensation expense in accordance with the applicable accounting guidance and the terms of the related award agreement. As of June 30, 2026 and December 31, 2025, had recorded accrued but unpaid royalties owed to the Director of Clinical Affairs of approximately $<span id="xdx_903_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_c20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorClinicalAffairMember_zPave0j6Rm2a" title="Consulting fee payable">392,000 and $<span id="xdx_907_eus-gaap--AccountsPayableAndAccruedLiabilitiesCurrent_iI_c20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--DirectorClinicalAffairMember_zbt0t5oLnrzh" title="Consulting fee payable">289,000, respectively. These amounts are included in accounts payable—related party and accrued expenses—related party in the Company’s consolidated balance sheets. Directors Leonard Osser On April 6, 2021, Leonard Osser entered into a succession agreement with the Company and U.S. Asian Consulting Group, LLC (“U.S. Asian”), a company of which Mr. Osser is a principal and, together with his wife, the sole members (the “Succession Agreement”). The Succession Agreement restructured certain compensation arrangements under Mr. Osser’s July 2017 employment agreement with the Company (the “Osser Employment Agreement”) and U.S. Asian’s July 2017 consulting agreement with the Company (the “Osser Consulting Agreement”). Under the Succession Agreement, annual compensation under the Osser Employment Agreement was reduced by $<span id="xdx_906_eus-gaap--IncreaseDecreaseInDeferredCompensation_di_c20170731__20170731__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrOsserViceChairmanOfBoardMember_zauhl1bYDhT" title="Increase decrease in deferred compensation">100,000 to $<span id="xdx_900_ecustom--EmploymentAgreementBaseCompensation_c20170731__20170731__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrOsserViceChairmanOfBoardMember_z8oJonsWQ6We" title="Employment agreement, base compensation">200,000, divided equally between cash and equity compensation. Annual compensation under the Osser Consulting Agreement was increased by $<span id="xdx_903_eus-gaap--IncreaseDecreaseInDeferredCompensation_c20170731__20170731__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrOsserViceChairmanOfBoardMember_zmYukFqGH4Cc" title="Increase (decrease) in compensation">100,000 to $<span id="xdx_906_ecustom--EmploymentAgreementBaseCompensation_c20170731__20170731__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrOsserViceChairmanOfBoardMember_zfiY67kCdFsi" title="Employment agreement, base compensation">200,000, also divided equally between cash and equity compensation. The equity compensation component was transferred from the Osser Employment Agreement to the Osser Consulting Agreement. On May 19, 2021, Mr. Osser stepped down as Interim Chief Executive Officer and assumed the role of Vice Chairman of the Board. In connection with his appointment as Vice Chairman and his continuing consulting services, Mr. Osser was granted options to purchase <span id="xdx_900_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_c20210519__20210519__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrOsserViceChairmanOfBoardMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_z1SDfPNen3ll" title="Options granted to purchase common stock">2,000,000 shares of the Company’s common stock at an exercise price equal to the fair market value of the common stock on the grant date. The options vest over <span id="xdx_903_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_dtY_c20210519__20210519__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrOsserViceChairmanOfBoardMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zF3kkkC2sK62" style="display: none" title="Options vesting period">5 five years and expire <span id="xdx_904_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod_dc_c20210519__20210519__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrOsserViceChairmanOfBoardMember__us-gaap--AwardTypeAxis__us-gaap--EmployeeStockOptionMember_zUG8ZtJSpwua" title="Options exercisable period">ten years from the date of grant. Mr. Osser resigned from the Company’s Board of Directors effective November 7, 2025. New Osser Agreement On June 19, 2026, the Company entered into a new agreement with Mr. Osser and U.S. Asian, effective as of April 1, 2026 (the “New Osser Agreement”). The New Osser Agreement amended the Osser Employment Agreement, the Osser Consulting Agreement and the Succession Agreement. With respect to periods before April 1, 2026, the New Osser Agreement provides that the Osser Consulting Agreement and the portions of the Succession Agreement relating to the Osser Consulting Agreement were canceled and terminated. As a result, the Company has no further obligation to make payments or provide benefits under those arrangements, whether in cash or shares. Mr. Osser also waived compensation and other amounts and benefits owed under the Osser Employment Agreement, subject to and conditioned upon the Company’s: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 1.8pt; margin-bottom: 1.8pt"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">payment of an aggregate of $<span id="xdx_904_ecustom--PaymentForPastDueAmount_c20260619__20260619__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrOsserViceChairmanOfBoardMember_zW0k7W4xE79f" title="Payments for past due amounts">64,080 of past-due amounts;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">payment of $<span id="xdx_90A_ecustom--PaymentForCatchUpAmount_c20260619__20260619__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrOsserViceChairmanOfBoardMember_zx5d52B7xfSh" title="Payments for catch up amount">75,000 as a catch-up payment relating to the period from July 2025 through March 2026; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">reimbursement of certain China-related travel and other expenses.</td></tr></table> Shares having a value of $<span id="xdx_904_eus-gaap--StockIssuedDuringPeriodValueNewIssues_c20260619__20260619__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrOsserViceChairmanOfBoardMember_zlRepqzy6uxa" title="Issuance of shares value">50,000 that were earned under the prior Osser agreements on or before March 31, 2026 remain deliverable in accordance with the applicable terms of those agreements. All shares that otherwise would have been earned for periods after March 31, 2026 were forfeited. Effective April 1, 2026, under the New Osser Agreement, Mr. Osser’s position was changed to Advisor to the Chief Executive Officer. The modified Osser Employment Agreement continues through July 17, 2027. During this period, Mr. Osser is entitled to annual cash compensation of $<span id="xdx_90D_eus-gaap--EmployeeBenefitsAndShareBasedCompensation_c20260619__20260619__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrOsserViceChairmanOfBoardMember_zXMKd80BfLRe" title="Employee benefit and cash compensation">48,000, continuation of health benefits for himself and his wife, and a car allowance, subject to the limitations provided in the New Osser Agreement. If the Company terminates Mr. Osser’s employment without cause, other than due to death or disability, if Mr. Osser terminates his employment for good reason, or if the Company fails to make a required payment within 30 days after its scheduled payment date, Mr. Osser is entitled to receive any amounts accrued through the termination or default date. He is also entitled to a lump-sum payment equal to the unpaid base salary, car allowance and healthcare payments that otherwise would have been payable through July 10, 2027. These amounts are payable in lieu of any termination-related payments under the prior Osser agreements. For the three and six months ended June 30, 2026, the Company recorded $<span id="xdx_90F_eus-gaap--DeferredCompensationArrangementWithIndividualCompensationExpense_c20260401__20260630__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrOsserViceChairmanOfBoardMember_ze1LG9Z0XGWj" title="Employee benefit and cash compensation">14,000 and $<span id="xdx_901_eus-gaap--DeferredCompensationArrangementWithIndividualCompensationExpense_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrOsserViceChairmanOfBoardMember_znzKaRyBViC5" title="Employee benefit and cash compensation">64,000 of expense under the Osser Employment Agreement. For the three and six months ended June 30, 2026, the Company recorded $<span id="xdx_904_eus-gaap--DeferredCompensationArrangementWithIndividualCompensationExpense_c20260401__20260630__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrOsserViceChairmanOfBoardMember_zzShWDxczfa5" title="Employee benefit and cash compensation">0.00 and $<span id="xdx_90C_eus-gaap--DeferredCompensationArrangementWithIndividualCompensationExpense_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrOsserViceChairmanOfBoardMember_zq48M2XUOaV4" title="Employee benefit and cash compensation">50,000 of expense under the Osser Consulting Agreement. For the three and six months ended June 30, 2025, the Company recorded $<span id="xdx_909_eus-gaap--DeferredCompensationArrangementWithIndividualCompensationExpense_c20250401__20250630__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrOsserViceChairmanOfBoardMember_zuS5JN8qB4Rc" title="Employee benefit and cash compensation">50,000 and $<span id="xdx_905_eus-gaap--DeferredCompensationArrangementWithIndividualCompensationExpense_c20250101__20250630__us-gaap--TypeOfArrangementAxis__custom--ConsultingAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrOsserViceChairmanOfBoardMember_z3My9huVPye1" title="Employee benefit and cash compensation">100,000 of expense under the Osser Employment Agreement. Mr. Osser and his wife also entered into lock-up agreements restricting the transfer of their shares of the Company’s common stock through April 20, 2027. The lock-up agreements do not restrict the transfer of <span id="xdx_90D_ecustom--TransferOfShares_pid_c20260101__20260630__us-gaap--TypeOfArrangementAxis__custom--EmploymentAgreementMember__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrOsserViceChairmanOfBoardMember_zIfzD1Zek4X2" title="Transfer of shares">363,339 shares for which the restrictive legends had previously been removed. Beneficial Ownership As of June 30, 2026, Mr. Osser beneficially owned<span id="xdx_90F_eus-gaap--InvestmentOwnedBalanceShares_iI_c20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrOsserViceChairmanOfBoardMember_zEqbqJkIIug5" title="Shares issued and owned"> 2,844,028 shares of the Company’s common stock and is entitled to receive an additional <span id="xdx_902_ecustom--SharesToBeIssuedAtEmploymentTermination_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrOsserViceChairmanOfBoardMember_zBDqBLjAG7Ik" title="Shares to be issued at employment termination">3,394,200 upon the termination of his Employment and Consulting Agreement. The previously disclosed statement that Mr. Osser was entitled to receive an additional <span id="xdx_902_ecustom--SharesToBeIssuedAtEmploymentTermination_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrOsserViceChairmanOfBoardMember_zgrHx2fMfv27" title="Shares to be issued at employment termination">3,394,200 shares upon termination of the Osser Employment Agreement has been removed because the New Osser Agreement waived and restructured the relevant compensation obligations and provides that shares relating to periods after March 31, 2026 were forfeited. Dr. D. Demesmin, Director As of February 2024, the University Pain Medicine Center (STEMMEE), of which Dr. D. Demesmin, a member of the Company’s Board of Directors, serves as Chief Executive Officer, agreed to purchase products from the Company under terms and conditions consistent with those offered to other medical pain clinics in the United States. STEMMEE purchased medical products totaling approximately $<span id="xdx_90C_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20260401__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityPainMedicineCenterSTEMMEEMember_zzHSfEEie6e">12,000 and $<span id="xdx_90F_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityPainMedicineCenterSTEMMEEMember_zq2zFS7QkgCa">18,000 for each of the three and six months ended June 30, 2026. STEMMEE purchased medical products totaling approximately $<span id="xdx_90C_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20250401__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityPainMedicineCenterSTEMMEEMember_zZYOoFKirxDa">15,000 and $<span id="xdx_905_eus-gaap--RelatedPartyTransactionAmountsOfTransaction_c20250101__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--UniversityPainMedicineCenterSTEMMEEMember_z3BVD7dIlDAd">21,000 for each of the three and six months ended June 30, 2025. The Company was owed approximately $ 9,600 and $ 25,500 as of June 30, 2026 and December 31, 2025, respectively. These amounts are regarded in related party accounts receivable. Arjan J. Haverhals, Director The Company entered into a consulting agreement with Jan Adriaan (Arjan) Haverhals (the “Haverhals Consulting Agreement”), effective January 1, 2025. The Haverhals Consulting Agreement continues for an indefinite term unless terminated in accordance with its terms. Either party may terminate the Haverhals Consulting Agreement upon 90 days’ prior written notice. The Company may terminate the Haverhals Consulting Agreement upon 30 days’ prior written notice in the event of Mr. Haverhals’ inability to provide services. Under the Haverhals Consulting Agreement, Mr. Haverhals is entitled to receive consulting fees at an annual rate of $<span id="xdx_904_eus-gaap--ProfessionalFees_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JanAdriaanArjanHaverhalsMember_zuqtvvyscbK" title="Consultants and professional services fees">350,000, payable monthly in arrears. For 2025, compensation was structured as follows: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">$<span id="xdx_904_ecustom--PaymentsForConsultingServices_c20250101__20250331__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JanAdriaanArjanHaverhalsMember_zn6IJ59CGyri" title="Consulting fee payable">150,000 for the first calendar quarter of 2025; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">$<span id="xdx_909_ecustom--PaymentsForConsultingServices_c20250401__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JanAdriaanArjanHaverhalsMember_z1K1R5dDLEI" title="Consulting fee payable"><span id="xdx_908_ecustom--PaymentsForConsultingServices_c20251001__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JanAdriaanArjanHaverhalsMember_zN0qfotBOxbd" title="Consulting fee payable">67,000 for each subsequent calendar quarter of 2025.</td></tr> </table> The Company recorded consulting expense of approximately $<span id="xdx_901_ecustom--PaymentsForConsultingServices_c20250401__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JanAdriaanArjanHaverhalsMember_zWpswdDdDvY4" title="Consulting fee payable">67,000 and $<span id="xdx_906_ecustom--PaymentsForConsultingServices_c20250101__20250630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--JanAdriaanArjanHaverhalsMember_zjJ5b1n2upp4" title="Consulting fee payable">216,000 for the three and six months ended June 30, 2025 related to the Haverhals Consulting Agreement. No expense was recorded for the three and six months ended June 30, 2026. Mr. Haverhals is entitled to reimbursement of reasonable expenses incurred in connection with the performance of his services. He serves as an independent contractor and is not eligible for Company-provided employee benefits, including health or accident insurance, life insurance, paid sick leave, or paid vacation. In connection with the Haverhals Consulting Agreement, Mr. Haverhals entered into the Company’s standard form of non-disclosure, non-solicitation, non-competition, and invention assignment agreement. As of June 30, 2026, and December 31, 2025, the Company owed Mr. Haverhals approximately $<span id="xdx_90B_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ArjanJHaverhalsAndDirectorMember_zprfPXaaJ8F4" title="Related party transaction, amounts of transaction owed">0 and $<span id="xdx_908_eus-gaap--RelatedPartyTransactionPurchasesFromRelatedParty_c20250101__20251231__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--ArjanJHaverhalsAndDirectorMember_z8OXI5Qqgega" title="Related party transaction, amounts of transaction owed">89,000, respectively, under the Haverhals Consulting Agreement, which is included in accounts payable—related party in the Company’s condensed consolidated balance sheets. Subsequent to December 31, 2025, Mr. Haverhals agreed to waive approximately $66,000 of amounts payable to him, which had previously been included in accounts payable—related party. Pursuant to the Haverhals Consulting Agreement, Mr. Haverhals is entitled to receive <span id="xdx_90C_ecustom--SharesToBeIssuedAfterEmployeesResignation_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrHaverhalsConsultantAndDirectorMember_zLLKRufN5jtb" title="Resignation of employees">895,013 shares of the Company’s common stock six months following his resignation as Chief Executive Officer, subject to the terms of the Haverhals Consulting Agreement. As of June 30, 2026, such shares had not been issued. At the Company’s Annual Meeting of Stockholders held on December 18, 2025, Mr. Haverhals was not re-elected to the Board of Directors, and his term as a director expired at the conclusion of the Annual Meeting. April 2025 Convertible Notes On April 9, 2025, the Company issued a series of promissory notes in the aggregate amount of $<span id="xdx_90B_eus-gaap--NotesPayable_iI_c20250409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNealGoldmanMsBenedettaCasamentoAndDrDidierDemesminMember_zT6Rplmk5EG1" title="Promissory notes">800,000 to Mr. Neal Goldman, Ms. Benedetta Casamento, and Dr. Didier Demesmin, each of whom is a director of the Company. The notes are due April 9, 2028 and bear interest at the annual rate of prime less <span id="xdx_90D_eus-gaap--DebtInstrumentInterestRateEffectivePercentage_iI_pid_dp_uPure_c20250409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNealGoldmanMsBenedettaCasamentoAndDrDidierDemesminMember_zSCZQwQVTHVj" title="Interest rate">2.50%, payable annually. All principal and interest shall be payable in cash and/or shares of common stock at the sole discretion of the Company. The notes are convertible into shares of common stock by the holder at any time and by the Company at maturity. If the Company sells equity securities for gross proceeds in excess of $<span id="xdx_902_ecustom--DebtInstrumentEquitySecuritiesIssuanceGrossProceedsBenchmark_c20250409__20250409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNealGoldmanMsBenedettaCasamentoAndDrDidierDemesminMember_zluyFxjQZbf6" title="Gross proceeds from sale of equity securities">4,000,000, the holders may request repayment of their note in either cash, shares of common stock or a combination of cash and shares; provided, that the holders would then be entitled to receive only so much cash as the net proceeds to the Company in such sale of equity securities, after payment of other indebtedness and other uses (other than working capital) specified as a use of the proceeds in the relevant offering or disclosure documentation, shall be in excess of $<span id="xdx_909_ecustom--DebtInstrumentEquitySecuritiesIssuanceGrossProceedsBenchmark_c20250409__20250409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNealGoldmanMsBenedettaCasamentoAndDrDidierDemesminMember_zjsnUCBiVg1g" title="Gross proceeds from sale of equity securities">4,000,000. Upon a liquidation event of the Company, as defined in the notes which includes a sale of the Company or assets, a merger, reorganization or combination transaction where the shareholders before the transaction own less than <span id="xdx_908_eus-gaap--SaleOfStockPercentageOfOwnershipBeforeTransaction_pid_dp_uPure_c20250409__20250409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNealGoldmanMsBenedettaCasamentoAndDrDidierDemesminMember_zjGjeq0PcXgl" title="Ownership percentage">50% of the Company after the transaction and a liquidation, dissolution or winding-up of the Company, the notes will be repaid in cash or its portion of any non-cash consideration. The conversion rate for any issuance of shares of common stock will be at the then fair value of a share of common stock, with the fair value being determined with reference to the public market price of a share of common stock, but not less than $<span id="xdx_904_eus-gaap--SharePrice_iI_c20250409__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MrNealGoldmanMsBenedettaCasamentoAndDrDidierDemesminMember_zqrtrPFQZrZ5" title="Market price">0.50. The notes are unsecured and have typical default terms. On April 20, 2026, the Company completed the Private Placement of 7,962,963 units at a purchase price of $0.27 per unit, generating gross proceeds of approximately $2.15 million, consisting of $1.80 million in cash and a reduction of $351,000 in outstanding principal of the Company’s Convertible Notes, the holders of which applied such principal amounts toward the purchase of units in the offering in lieu of cash. Each of Mr. Neal Goldman, Ms. Benedetta Casamento and Dr. Didier Demesmin reduced their outstanding aggregate principal amount of Convertible Notes by $219,375, $87,750 and $43,875, respectively and received 812,501, <span id="xdx_908_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_c20260420__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--MsBenedettaCasamentoMember_zhFAVQerw0Zf">325,000 and 162,500 shares and warrants, respectively. On July 24, 2026, the Company received notices of conversion (the “Conversion Notices”) from Benedetta Casamento, Dr. Didier Demesmin and Neal Goldman, each of whom is a director of the Company (collectively, the “Holders”), with respect to the Company’s amended and restated Convertible Notes. The Conversion Notices constitute the Holders’ elections, pursuant to Section 5(a) of the Convertible Bridge Notes, to convert the remaining outstanding principal amount and accrued interest under their respective Convertible Notes into shares of the Company’s common stock, effective automatically at such time as the Fair Value (as defined in the Convertible Notes) of the common stock is not less than $0.50 per share and the applicable Holder is permitted to buy and sell securities of the Company in compliance with the Company’s Insider Trading Policy. BP4 S.r.l. / Innovest S.p.A. BP4 S.r.l. / Innovest S.p.A.\n\nBP4 S.r.l. (“BP4”) is a significant shareholder of the Company, beneficially owning approximately <span id="xdx_90B_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20260101__20260630__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovestSPAMember_zXHWpORGIWkc" title="Interest rate">11.31% of the Company’s outstanding common stock, and is considered a related party. On January 15, 2026, the Company entered into an Amended and Restated Memorandum of Understanding (the “MOU”) with Innovest S.p.A., as the holder of certain consent and blockage rights with respect to BP4. <span id="xdx_90E_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20260115__20260115__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--InnovestSPAMember_zhJZ5kZW8Pq9" title="Related party transaction description of transaction">Pursuant to the MOU, and subject to certain conditions, BP4 agreed to enter into a lock-up agreement pursuant to which it would not distribute or sell any of its shares of capital stock of the Company for twelve months following consummation of a $2.5 million offering by the Company. The lock-up provides for early release if the Company’s stock price exceeds specified thresholds for a defined period, permitting partial distributions of shares to BP4’s quotaholders. The Company paid BP4 $60,000 in respect of additional disbursements accumulated in connection with the transaction contemplated by the MOU, which payments are subject to an aggregate cap of $100,000. On March 31, 2026, the Company entered into an amendment to the MOU to, among other things, revise the definition of “Qualified Offering” in order to facilitate an offering by the Company, and required certain additional persons and entities to enter into lock-up agreement. The Private Placement on April 20, 2026 satisfied the requirement of a “Qualified Offering” and the required additional persons and entities signed lock-up agreements. Bendetta Casamento-Executive Chairman. On June 24, 2026, the Board, with Benedetta Casamento not in attendance, determined, in view of the increased role played, and to continue to be played, by Ms. Casamento in the business and affairs of the Company, to approve the recommendation of the Compensation Committee, electing Ms. Casamento as Executive Chairman. Prior to becoming Executive Chairman, Ms. Casamento has been the Chairman of the Board of the Company as an independent director, devoting substantial time and effort to the Company. As Executive Chairman, she is expected to enhance executive leadership, strategic oversight, investor engagement, and corporate development support for the Company. Her duties and responsibilities as Executive Chairman include, without limitation, working collaboratively with the Chief Executive Officer and senior management to establish and execute the Company’s strategic objectives, supporting corporate development initiatives, including strategic partnerships, acquisitions, licensing opportunities, and commercial growth initiatives, assisting with investor relations activities, capital markets initiatives, financing transactions, and communications with current and prospective investors, and advising management on operational, financial, regulatory, and governance matters affecting the Company. For her services as Executive Chairman, the Company has agreed to pay her, <span id="xdx_90E_eus-gaap--RelatedPartyTransactionDescriptionOfTransaction_c20260624__20260624__us-gaap--RelatedPartyTransactionsByRelatedPartyAxis__custom--BenedettaCasamentoMember_z8Ax0zCVl888" title="Related party transaction description of transaction">(1) a salary at the rate of $75,000 per year as supplemental cash compensation, (2) 115.385% of the amount per year she would receive each year she is Executive Chairman if she remained an independent director and for being the chair and member of the committees she was chair and a member for such period (the “Director Equivalent”), in equity awards, in lieu of the equity she had previously been receiving as compensation in respect of such Board and committee service, and otherwise with the same vesting and other terms as awards of equity to directors for such Board and committee service, and (3) a one-time grant of $100,000 of shares of restricted common stock of the Company vesting on July 1, 2026. For the current year, the amount referred to in clause (1) above shall be $75,000, based on the Director Equivalent of $65,000. As Executive Chairman, Ms. Casamento would also be entitled to participate in the employee benefit plans and programs of the Company in which other senior executives of the Company participate, subject to eligibility requirements, enrollment criteria, and the other terms and conditions of such plans and programs. Ms. Casamento is no longer considered an independent director, and she resigned from the committees on which she served. On June 24, 2026, Ms. Casamento and the Company entered into an employment letter agreement with respect to her status as Executive Chairman. The foregoing description of the material terms of such letter agreement does not purport to be complete and is qualified in its entirety by reference to such agreement, a copy of which, previously filed with the Company’s Form 8-K, is an as Exhibit hereto.

222000

471000

285000

772000

667000

1100000

151000

246000

119000

232000

25000 50000 39000 78000

392000

289000

-100000

200000

100000

200000

2000000

P5Y

P10Y

64080 75000

50000

48000

14000

64000

0.00

50000

100000

363339

2844028

3394200 3394200

12000

18000

15000

21000

350000

150000 67000 67000 67000 216000

89000

66000 895013

800000

0.0250

4000000 4000000

0.50

7962963

0.27

2150000

1800000

351000

219375

87750

43875

812501

325000

162500

0.50

0.1131

Pursuant to the MOU, and subject to certain conditions, BP4 agreed to enter into a lock-up agreement pursuant to which it would not distribute or sell any of its shares of capital stock of the Company for twelve months following consummation of a $2.5 million offering by the Company. The lock-up provides for early release if the Company’s stock price exceeds specified thresholds for a defined period, permitting partial distributions of shares to BP4’s quotaholders. The Company paid BP4 $60,000 in respect of additional disbursements accumulated in connection with the transaction contemplated by the MOU, which payments are subject to an aggregate cap of $100,000.

(1) a salary at the rate of $75,000 per year as supplemental cash compensation, (2) 115.385% of the amount per year she would receive each year she is Executive Chairman if she remained an independent director and for being the chair and member of the committees she was chair and a member for such period (the “Director Equivalent”), in equity awards, in lieu of the equity she had previously been receiving as compensation in respect of such Board and committee service, and otherwise with the same vesting and other terms as awards of equity to directors for such Board and committee service, and (3) a one-time grant of $100,000 of shares of restricted common stock of the Company vesting on July 1, 2026. For the current year, the amount referred to in clause (1) above shall be $75,000, based on the Director Equivalent of $65,000.

NOTE 12 — COMMITMENTS (1) Contract Manufacturing Agreement Milestone Scientific has informal arrangements with third-party manufacturers of the STA devices and epidural instruments pursuant to which they manufacture these products under specific purchase orders but without any long-term contract or minimum purchase commitment. The Company has a purchase commitment for the delivery of <span id="xdx_909_ecustom--PurchaseCommitmentNumberOfUnits_uInteger_c20260101__20260630__us-gaap--PurchaseCommitmentExcludingLongtermCommitmentAxis__custom--PurchaseCommitmentForDevicesMember_z1zIlrD4uH94" title="Purchase commitment number of units">1,650 STA instruments as of June 30, 2026. As of June 30, 2026 and December 31, 2025, the purchase order commitment was approximately <span id="xdx_90E_eus-gaap--PurchaseCommitmentRemainingMinimumAmountCommitted_iI_c20260630__us-gaap--PurchaseCommitmentExcludingLongtermCommitmentAxis__custom--PurchaseCommitmentForDevicesMember_zOEExFNwDTYc">871,000 respectively, and approximately $1.4 million was paid and reported in advance on contracts in the unaudited condensed consolidated balance sheet. The Company also had advances on contracts of approximately $364,000 related to materials for future purchase orders for the manufacture of its next-generation dental instrument. The advances in contracts represent funding for future epidural instruments and epidural replacement parts. As of June 30, 2026 and December 31, 2025, the Company also has advances on an open purchase order for long lead items for a future purchase order for the manufacturing of Epidural instruments of approximately $<span id="xdx_902_eus-gaap--AdvancesOnInventoryPurchases_iI_c20260630__us-gaap--PurchaseCommitmentExcludingLongtermCommitmentAxis__custom--ContractsForFundingOfFutureEpiduralInstrumentsAndPartsMember_z1dIveReTHJ8" title="Advances on inventory purchases"><span id="xdx_90E_eus-gaap--AdvancesOnInventoryPurchases_iI_c20251231__us-gaap--PurchaseCommitmentExcludingLongtermCommitmentAxis__custom--ContractsForFundingOfFutureEpiduralInstrumentsAndPartsMember_z3aiRa62Qcr" title="Advances on inventory purchases">34,000, respectively. (2) Operating Leases The Company identified and assessed the following significant assumptions in recognizing its right-of-use assets and corresponding lease liabilities: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%"> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in"> </td> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.5in">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">As the Company’s leases do not provide an implicit rate, the Company estimated the incremental borrowing rate in calculating the present value of the lease payments. The Company has utilized its incremental borrowing rate based on the long-term borrowing costs of comparable companies in the Medical Device industry.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Since the Company elected to account for each lease component and its associated non-lease components as a single combined lease component, all contract consideration was allocated to the combined lease component.</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif"> </td> <td style="font: 10pt Times New Roman, Times, Serif">●</td> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">The expected lease terms include non-cancellable lease periods. Renewal option periods are not included in the determination of the lease terms as they were not reasonably certain to be exercised.</td></tr> </table> The components of lease expense were as follows: SCHEDULE OF COMPONENTS OF LEASE EXPENSE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20260401__20260630_zoaDYZxglMh4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20250401__20250630_z8WLDkhIeMR3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20260101__20260630_zxkjT2Kr8ord" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20250101__20250630_zTPbeYVZrzKh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three months ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Six months ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeasePayments_zPN1bgntIVce" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Cash paid for operating lease liabilities</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">31,882</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">31,882</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">31,882</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">63,764</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FinanceLeaseInterestPaymentOnLiability_zS0pSH9qlDZ5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Cash paid for finance lease liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,417</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,417</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,417</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,834</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Weighted Average Remaining Lease Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Finance leases (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 3.27 years </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 4.50 years </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating leases (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 0.75 years </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 1.75 years </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average discount rate – operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9.20</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9.20</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average discount rate – finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9.20</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9.20</td><td style="text-align: left">%</td></tr> </table>

1650

871000

1400000

364000

34000

The components of lease expense were as follows: SCHEDULE OF COMPONENTS OF LEASE EXPENSE <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"> <tr style="display: none; vertical-align: bottom"> <td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49C_20260401__20260630_zoaDYZxglMh4" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_49F_20250401__20250630_z8WLDkhIeMR3" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_497_20260101__20260630_zxkjT2Kr8ord" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" id="xdx_493_20250101__20250630_zTPbeYVZrzKh" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Three months ended</td><td style="font-weight: bold"> </td><td style="font-weight: bold"> </td> <td colspan="6" style="font-weight: bold; text-align: center">Six months ended</td><td style="font-weight: bold"> </td></tr> <tr style="vertical-align: bottom"> <td style="font-weight: bold; text-align: right"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2026</td><td style="padding-bottom: 1pt; font-weight: bold"> </td><td style="font-weight: bold; padding-bottom: 1pt"> </td> <td colspan="2" style="border-bottom: Black 1pt solid; font-weight: bold; text-align: center">June 30, 2025</td><td style="padding-bottom: 1pt; font-weight: bold"> </td></tr> <tr id="xdx_40F_eus-gaap--OperatingLeasePayments_zPN1bgntIVce" style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="width: 36%; text-align: left">Cash paid for operating lease liabilities</td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">31,882</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">31,882</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">31,882</td><td style="width: 1%; text-align: left"> </td><td style="width: 2%"> </td> <td style="width: 1%; text-align: left">$</td><td style="width: 12%; text-align: right">63,764</td><td style="width: 1%; text-align: left"> </td></tr> <tr id="xdx_40E_eus-gaap--FinanceLeaseInterestPaymentOnLiability_zS0pSH9qlDZ5" style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Cash paid for finance lease liabilities</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,417</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,417</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">3,417</td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">6,834</td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="font-weight: bold">Weighted Average Remaining Lease Term</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Finance leases (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 3.27 years </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 4.50 years </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Operating leases (years)</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 0.75 years </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> 1.75 years </td><td style="text-align: left"> </td></tr> <tr style="vertical-align: bottom; background-color: White"> <td style="text-align: left">Weighted-average discount rate – operating leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9.20</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9.20</td><td style="text-align: left">%</td></tr> <tr style="vertical-align: bottom; background-color: rgb(204,238,255)"> <td style="text-align: left">Weighted-average discount rate – finance leases</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right"> </td><td style="text-align: left"> </td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9.20</td><td style="text-align: left">%</td><td> </td> <td style="text-align: left"> </td><td style="text-align: right">9.20</td><td style="text-align: left">%</td></tr> </table>

31882

63764

3417

6834

P3Y3M7D

P4Y6M

P0Y9M

P1Y9M

0.0920

NOTE 13 — SUBSEQUENT EVENT On July 27, 2026, the Company held its 2026 Annual Meeting of Stockholders. At the Annual Meeting, the Company’s stockholders: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Elected Benedetta Casamento, Neal Goldman, Eric Hines, Dr. Didier Demesmin and Dr. Dawood Sayed to serve as directors until the Company’s 2027 Annual Meeting of Stockholders or until their respective successors are duly elected and qualified;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Approved an amendment to the Company’s Restated Certificate of Incorporation to increase the number of authorized shares of common stock from 125,000,000 to 135,000,000;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Approved an amendment to the Company’s Amended and Restated 2020 Equity Incentive Plan to increase the number of shares of common stock reserved and available for issuance under the plan from <span id="xdx_90F_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20260726__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_z5av7ZmYIq2" title="Shares of common stock reserved and available">11,500,000 to <span id="xdx_90C_eus-gaap--CommonStockCapitalSharesReservedForFutureIssuance_iI_c20260727__us-gaap--SubsequentEventTypeAxis__us-gaap--SubsequentEventMember_zz0QT77F5CHj" title="Shares of common stock reserved and available">28,750,000;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Approved, on a non-binding advisory basis, the compensation of the Company’s named executive officers; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Ratified the appointment of Grassi & Co., CPAs, P.C. as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026.</td></tr></table> On July 29, 2026, the Board of Directors: <table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; margin-top: 0; margin-bottom: 0"><tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Re-elected each of Kelly Ulto and Greg Shilling to serve as a director of the Company, effective July 27, 2026, until the Company’s 2027 annual meeting of stockholders (the “2027 Annual Meeting”) or until their respective successor is duly elected and qualified, or such director’s earlier resignation or removal</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Reaffirmed its determination that each of Ms. Ulto and Mr. Shilling is independent under the applicable NYSE American listing standards;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Reaffirmed its determination that Ms. Ulto qualifies as an “audit committee financial expert,” as defined in Item 407(d)(5) of Regulation S-K as well as Rule 10A-3 under the Securities Exchange Act of 1934, as applicable;</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Appointed Ms. Ulto as Chair of the Audit Committee and as a member of the Compensation Committee and the Nominating and Corporate Governance Committee; and</td></tr> <tr style="font: 10pt Times New Roman, Times, Serif; vertical-align: top"> <td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in"></td><td style="font: 10pt Times New Roman, Times, Serif; width: 0.25in">●</td><td style="font: 10pt Times New Roman, Times, Serif; text-align: justify">Appointed Mr. Shilling as Chair of the Compensation Committee and as a member of the Audit Committee and the Nominating and Corporate Governance Committee.</td></tr></table> These events occurred subsequent to June 30, 2026 and did not require adjustment to the Company’s unaudited condensed consolidated financial statements.

125000000

135000000

11500000

28750000

Includes 4,000,000 stock options exchanged pursuant to the Exchange Program